≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Myotonic disorders

DOID EFO Endpoint Browser PheWeb

G6_MYOTDIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G71.1
  • Hospital discharge: ICD-9 — 3592A
  • Hospital discharge: ICD-8 — 33020
  • Cause of death: ICD-10 — G71.1
  • Cause of death: ICD-9 — 3592A
  • Cause of death: ICD-8 — 33020

2 out of 7 registries used, show all original rules.

309

4. Check minimum number of events

None

309

5. Include endpoints

None

309

6. Filter based on genotype QC (FinnGen only)

295

Control definitions (FinnGen only)

Control exclude
G6_MYONEU

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
G71
Name in latin
Morbositates myotonicae

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2311 1166 1126
Only index persons 1965 1019 946
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.03
Only index persons 0.04 0.04 0.04
Median age at first event (years)
Whole population 44.33 44.69 43.83
Only index persons 43.13 43.84 42.36

-FinnGen-

Key figures

All Female Male
Number of individuals 295 173 122
Unadjusted period prevalence (%) 0.06 0.06 0.06
Median age at first event (years) 48.11 48.07 48.16

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
309
Matched controls
3090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G71.18
ICD-10 Finland
Other myotonic disease
+∞
145.7
128
*
G71.11
ICD-10 Finland
Dystrophia myotonica [Steinert]
+∞
135.7
120
*
Z31.5
ICD-10 Finland
Genetic counselling
19.2
133.2
126
107
G71.12
ICD-10 Finland
Myotonia congenita
+∞
123.4
110
*
G72.9
ICD-10 Finland
Myopathy, unspecified
548.3
48.8
47
*
R1250
NOMESCO Finland
Evaluation of functional capability
12.6
40.6
42
38
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.3
36.5
71
139
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
+∞
32.9
31
*
G71.8
ICD-10 Finland
Other primary disorders of muscles
+∞
29.7
28
*
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
29.7
28
*
G71.1
ICD-10 Finland
Myotonic disorders
307.9
28.2
28
*
L28
ICPC
Limited function/disability (L)
4.2
26.1
89
274
N99
ICPC
Neurological disease other
30.0
22.7
30
11
SPAT1215
SPAT
Assessment of need for medical rehabilitation
7.2
20.4
32
49
XF404
NOMESCO Finland
Ambulatory ECG
4.6
19.1
50
124
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.5
19.1
40
82
H26.02
ICD-10 Finland
Presenil cataract
8.4
18.6
25
32
N03AF01
ATC
carbamazepine; oral, rectal
5.4
18.1
38
78
N03AX09
ATC
lamotrigine; oral
5.0
17.9
42
95
G71.00
ICD-10 Finland
Muscular dystrophy benign [Becker]
+∞
17.9
17
*
C01BB02
ATC
mexiletine; systemic
190.5
17.7
18
*
N03AE01
ATC
clonazepam; systemic
4.9
15.9
37
83
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
157.1
14.6
15
*
J96.1
ICD-10 Finland
Chronic respiratory failure
15.4
14.3
23
16
L19
ICPC
Muscle symptom/complaint NOS
6.3
13.7
24
41
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.0
13.6
73
290
G71.28
ICD-10 Finland
Other congenital myopathy
+∞
12.6
12
*
SPAT1229
SPAT
Assessment of need for aid
4.5
12.4
32
78
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.8
12.3
41
121
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.5
12.1
110
567
3592A
ICD-9 Finland
Muscular dystrophies and other myopathies, Myotonic disorders
+∞
11.5
11
*
G71.0
ICD-10 Finland
Muscular dystrophy
+∞
11.5
11
*
N29
ICPC
Neurological sympt/complt other
11.2
11.5
21
20
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.9
11.2
58
225
Z3226
NOMESCO Finland
Physiotherapist
2.7
11.1
74
327
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.5
11.0
90
439
XA800
NOMESCO Finland
Neuropsychological investigation
3.9
10.6
32
88
NXL00
NOMESCO Finland
Biopsy of muscle
+∞
10.5
10
*
G71.14
ICD-10 Finland
Paramyotonia congenita
+∞
10.5
10
*
RF410, ,
NOMESCO Finland
19.6
10.4
15
8
RF420, ,
NOMESCO Finland
15.3
10.1
16
11
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
4.5
10.0
25
59
R42
ICD-10 Finland
Dizziness and giddiness
2.5
10.0
79
378
H26.4
ICD-10 Finland
After-cataract
3.5
9.8
35
108
G72.8
ICD-10 Finland
Other specified myopathies
56.8
9.7
11
*
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
3.3
9.6
38
125
R4120
NOMESCO Finland
Occupational therapy
3.4
9.2
35
112
RF210, ,
NOMESCO Finland
5.1
9.0
19
39
K80.2
ICD-10 Finland
Calculus of gallbladder without cholecystitis
2.8
8.7
48
191
N03AX12
ATC
[U] gabapentin; oral
2.4
8.4
65
306
N28
ICPC
Limited function/disability (N)
9.9
8.4
16
17
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
8.4
8
*
R4110
NOMESCO Finland
Physiotherapy
2.1
8.3
98
550
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
4.4
8.3
21
50
L99
ICPC
Musculoskeletal disease other
7.2
8.2
19
28
A28
ICPC
Limited function/disability NOS
2.6
8.1
50
211
G47.3
ICD-10 Finland
Sleep apnoea
2.2
8.0
90
495
N03AX16
ATC
[U] pregabalin
2.2
7.8
83
447
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
7.5
90
506
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
2.1
7.4
80
432
G71.10
ICD-10 Finland
Myotonia drug-induced
+∞
7.3
7
*
Z82.6
ICD-10 Finland
Family history of arthritis and other diseases of the musculoskeletal system and connective tissue
+∞
7.3
7
*
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.5
7.3
26
80
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
7.6
7.3
16
22
RF120, ,
NOMESCO Finland
12.4
7.1
12
10
R4110, ,
SPAT
2.4
7.0
53
246
Z3231
NOMESCO Finland
Registered nurse
2.0
6.9
93
544
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.6
6.8
42
177
N06AX21
ATC
duloxetine; oral
2.4
6.6
51
239
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.8
6.6
20
55
M03BX01
ATC
baclofen; systemic
5.9
6.6
17
30
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
71.3
6.4
7
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.1
6.4
66
348
M79.1
ICD-10 Finland
Myalgia
2.2
6.4
62
319
TNX05
NOMESCO Finland
Simple incision of soft tissue, unspecified region
+∞
6.3
6
*
H28.2*G71.11
ICD-10 Finland
Myotonic cataract
+∞
6.3
6
*
G71.3
ICD-10 Finland
Mitochondrial myopathy, not elsewhere classified
+∞
6.3
6
*
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
3.9
6.2
18
48
R5110, ,
SPAT
2.8
6.1
31
118
R03AC02
ATC
salbutamol; inhalant
1.8
6.0
184
1383

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
1.5e+00
3.0e+00
2.4e+00
—
3.2e+00
3.9e+00
2.9e+00
cases:25.99%
controls:7.32%
cases:40.33%
controls:3.35%
cases:7.87%
controls:0.76%
—
—
cases:13.11%
controls:0.62%
cases:60.40%
controls:2.98%
cases:62.72%
controls:8.10%
79
222
225
2812
123
102
182
2942
24
23
281
3021
—
40
19
265
3023
180
90
118
2928
175
229
104
2597
Outpatient Visit
OP [9202]
6.7e-01
1.3e+00
6.3e-01
6.3e+00
1.2e+00
1.5e+00
1.3e+00
cases:75.99%
controls:61.77%
cases:70.82%
controls:40.18%
cases:16.72%
controls:9.63%
cases:67.87%
controls:0.39%
cases:24.59%
controls:8.84%
cases:76.17%
controls:41.55%
cases:90.32%
controls:72.05%
231
1874
73
1160
216
1223
89
1821
51
293
254
2751
207
12
98
3032
75
269
230
2773
227
1254
71
1764
252
2036
27
790
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
2.2e+00
3.9e+00
—
—
—
3.0e+00
2.0e+00
cases:5.92%
controls:0.66%
cases:9.18%
controls:0.20%
—
—
—
—
—
—
cases:3.36%
controls:0.17%
cases:5.73%
controls:0.78%
18
20
286
3014
28
6
277
3038
—
—
—
10
5
288
3013
16
22
263
2804
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
9.3e-01
3.1e+00
—
1.0e+50
—
4.4e+00
3.0e+00
cases:2.30%
controls:0.92%
cases:10.49%
controls:0.53%
—
—
cases:11.15%
controls:0.00%
—
—
cases:18.12%
controls:0.27%
cases:12.90%
controls:0.71%
7
28
297
3006
32
16
273
3028
—
34
0
271
3044
—
54
8
244
3010
36
20
243
2806
Genetic counselling
Z31.5 [45590715]
9.8e-01
3.3e+00
—
1.0e+50
—
3.9e+00
2.8e+00
cases:1.64%
controls:0.63%
cases:9.51%
controls:0.39%
—
—
cases:7.21%
controls:0.00%
—
—
cases:13.42%
controls:0.30%
cases:9.68%
controls:0.67%
5
19
299
3015
29
12
276
3032
—
22
0
283
3044
—
40
9
258
3009
27
19
252
2807
clonazepam; oral, parenteral
N03AE01 [21604415]
1.6e+00
2.7e+00
—
—
—
2.9e+00
2.7e+00
cases:2.96%
controls:0.63%
cases:4.59%
controls:0.33%
—
—
—
—
—
—
cases:4.70%
controls:0.27%
cases:6.09%
controls:0.42%
9
19
295
3015
14
10
291
3034
—
—
—
14
8
284
3010
17
12
262
2814
Physical Medicine And Rehabilitation
25 [38004468]
1.0e+00
1.9e+00
1.4e+00
—
3.1e+00
2.1e+00
1.4e+00
cases:13.49%
controls:5.27%
cases:11.80%
controls:1.97%
cases:1.64%
controls:0.39%
—
—
cases:4.92%
controls:0.23%
cases:14.77%
controls:2.09%
cases:22.22%
controls:6.44%
41
160
263
2874
36
60
269
2984
5
12
300
3032
—
15
7
290
3035
44
63
254
2955
62
182
217
2644
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.3e+00
2.5e+00
—
—
1.0e+50
2.2e+00
1.3e+00
cases:7.89%
controls:2.34%
cases:11.48%
controls:1.08%
—
—
—
—
cases:2.62%
controls:0.00%
cases:9.73%
controls:1.23%
cases:14.34%
controls:4.46%
24
71
280
2963
35
33
270
3011
—
—
8
0
297
3042
29
37
269
2981
40
126
239
2700
Office Visit
OMOP4822458 [581477]
6.1e-01
1.6e+00
1.2e+00
1.0e+50
2.4e+00
1.7e+00
1.2e+00
cases:12.50%
controls:7.19%
cases:10.82%
controls:2.40%
cases:1.64%
controls:0.49%
cases:2.30%
controls:0.00%
cases:3.61%
controls:0.33%
cases:9.73%
controls:1.86%
cases:19.00%
controls:6.40%
38
218
266
2816
33
73
272
2971
5
15
300
3029
7
0
298
3044
11
10
294
3032
29
56
269
2962
53
181
226
2645
Cardiology
6 [38004451]
4.6e-01
9.1e-01
—
—
2.6e+00
1.9e+00
1.6e+00
cases:7.57%
controls:4.91%
cases:5.90%
controls:2.46%
—
—
—
—
cases:2.62%
controls:0.20%
cases:14.09%
controls:2.42%
cases:25.09%
controls:6.44%
23
149
281
2885
18
75
287
2969
—
—
8
6
297
3036
42
73
256
2945
70
182
209
2644
gabapentin; oral
N02BF01 [955005]
7.7e-01
1.6e+00
—
—
1.9e+00
1.6e+00
1.2e+00
cases:3.62%
controls:1.71%
cases:3.93%
controls:0.79%
—
—
—
—
cases:2.30%
controls:0.36%
cases:4.03%
controls:0.83%
cases:7.17%
controls:2.34%
11
52
293
2982
12
24
293
3020
—
—
7
11
298
3031
12
25
286
2993
20
66
259
2760
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
9.6e-01
7.6e-01
—
—
2.7e+00
1.5e+00
1.2e+00
cases:6.91%
controls:2.77%
cases:2.62%
controls:1.25%
—
—
—
—
cases:2.30%
controls:0.16%
cases:4.70%
controls:1.13%
cases:10.04%
controls:3.33%
21
84
283
2950
8
38
297
3006
—
—
7
5
298
3037
14
34
284
2984
28
94
251
2732
Ambulatory ECG
XF404 [2001303370]
—
—
—
—
—
3.1e+00
2.6e+00
—
—
—
—
—
—
—
—
—
—
cases:5.03%
controls:0.23%
cases:5.73%
controls:0.46%
—
—
—
—
—
15
7
283
3011
16
13
263
2813
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.1e+00
1.6e+00
—
—
—
1.6e+00
9.9e-01
cases:6.91%
controls:2.47%
cases:5.25%
controls:1.08%
—
—
—
—
—
—
cases:6.71%
controls:1.39%
cases:9.68%
controls:3.82%
21
75
283
2959
16
33
289
3011
—
—
—
20
42
278
2976
27
108
252
2718
pregabalin; oral
N02BF02 [955152]
1.0e+00
1.6e+00
—
—
—
1.2e+00
1.3e+00
cases:7.24%
controls:2.70%
cases:5.90%
controls:1.25%
—
—
—
—
—
—
cases:4.36%
controls:1.33%
cases:10.75%
controls:3.18%
22
82
282
2952
18
38
287
3006
—
—
—
13
40
285
2978
30
90
249
2736
Paediatric neurology
421 [44777781]
1.6e+00
1.7e+00
—
1.0e+50
—
2.4e+00
2.6e+00
cases:1.64%
controls:0.33%
cases:1.64%
controls:0.30%
—
—
cases:1.97%
controls:0.00%
—
—
cases:3.69%
controls:0.33%
cases:4.66%
controls:0.35%
5
10
299
3024
5
9
300
3035
—
6
0
299
3044
—
11
10
287
3008
13
10
266
2816
Functional capacity evaluation
443351003 [40481051]
1.2e+00
1.9e+00
—
—
—
3.0e+00
2.1e+00
cases:2.63%
controls:0.82%
cases:1.97%
controls:0.30%
—
—
—
—
—
—
cases:6.71%
controls:0.36%
cases:8.24%
controls:1.13%
8
25
296
3009
6
9
299
3035
—
—
—
20
11
278
3007
23
32
256
2794
Supplier / Service Provider
OMOP5117446 [33004]
-1.1e+00
-2.5e-01
—
—
1.0e+50
2.7e+00
3.4e+00
cases:10.86%
controls:27.09%
cases:7.54%
controls:9.46%
—
—
—
—
cases:1.64%
controls:0.00%
cases:5.70%
controls:0.40%
cases:16.13%
controls:0.64%
33
822
271
2212
23
288
282
2756
—
—
5
0
300
3042
17
12
281
3006
45
18
234
2808
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
2.7e+00
—
—
—
—
—
2.3e+00
cases:2.30%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:2.51%
controls:0.25%
7
5
297
3029
—
—
—
—
—
7
7
272
2819
Observation for other suspected cardiovascular diseases
Z03.5 [45590692]
—
—
—
—
—
2.2e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.27%
cases:5.38%
controls:0.46%
—
—
—
—
—
7
8
291
3010
15
13
264
2813
Pharmacy visit
OMOP4822462 [581458]
3.1e-01
8.5e-01
5.7e-01
1.4e+00
6.4e-01
1.2e+00
9.9e-01
cases:93.09%
controls:90.77%
cases:88.85%
controls:77.30%
cases:48.85%
controls:35.02%
cases:5.90%
controls:1.54%
cases:50.49%
controls:34.88%
cases:91.61%
controls:77.10%
cases:97.49%
controls:93.52%
283
2754
21
280
271
2353
34
691
149
1066
156
1978
18
47
287
2997
154
1061
151
1981
273
2327
25
691
272
2643
7
183
duloxetine; oral
N06AX21 [21604749]
1.2e+00
1.4e+00
—
—
—
1.5e+00
1.6e+00
cases:3.62%
controls:1.15%
cases:3.28%
controls:0.79%
—
—
—
—
—
—
cases:3.02%
controls:0.66%
cases:6.09%
controls:1.31%
11
35
293
2999
10
24
295
3020
—
—
—
9
20
289
2998
17
37
262
2789
Physiotherapist
Z3226 [2001311560]
8.8e-01
1.6e+00
—
—
2.3e+00
2.5e+00
2.0e+00
cases:4.28%
controls:1.81%
cases:2.62%
controls:0.56%
—
—
—
—
cases:1.64%
controls:0.16%
cases:5.37%
controls:0.46%
cases:7.53%
controls:1.10%
13
55
291
2979
8
17
297
3027
—
—
5
5
300
3037
16
14
282
3004
21
31
258
2795
Occupational therapy
R4120 [2001310234]
—
—
—
—
—
2.6e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.23%
cases:3.58%
controls:0.60%
—
—
—
—
—
9
7
289
3011
10
17
269
2809
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
1.7e+00
2.6e+00
—
—
—
2.1e+00
1.8e+00
cases:2.30%
controls:0.43%
cases:2.62%
controls:0.20%
—
—
—
—
—
—
cases:1.68%
controls:0.20%
cases:3.58%
controls:0.64%
7
13
297
3021
8
6
297
3038
—
—
—
5
6
293
3012
10
18
269
2808
carbamazepine; oral, rectal
N03AF01 [21604417]
1.6e+00
1.3e+00
—
—
—
2.3e+00
2.0e+00
cases:2.63%
controls:0.56%
cases:1.97%
controls:0.53%
—
—
—
—
—
—
cases:4.70%
controls:0.50%
cases:5.02%
controls:0.74%
8
17
296
3017
6
16
299
3028
—
—
—
14
15
284
3003
14
21
265
2805
Standard cardiac ultrasound examination
FM1AE [2001303278]
8.3e-02
1.2e+00
—
—
—
2.3e+00
1.9e+00
cases:1.64%
controls:1.52%
cases:1.64%
controls:0.49%
—
—
—
—
—
—
cases:6.71%
controls:0.73%
cases:11.47%
controls:1.95%
5
46
299
2988
5
15
300
3029
—
—
—
20
22
278
2996
32
55
247
2771
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
6.2e-01
1.0e+00
—
—
2.1e+00
7.5e-01
9.7e-01
cases:8.22%
controls:4.58%
cases:7.87%
controls:3.06%
—
—
—
—
cases:3.28%
controls:0.43%
cases:6.04%
controls:2.95%
cases:18.28%
controls:7.78%
25
139
279
2895
24
93
281
2951
—
—
10
13
295
3029
18
89
280
2929
51
220
228
2606
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
1.8e+00
—
—
—
—
2.2e+00
1.8e+00
cases:1.97%
controls:0.33%
—
—
—
—
—
—
—
—
cases:2.68%
controls:0.30%
cases:3.58%
controls:0.60%
6
10
298
3024
—
—
—
—
8
9
290
3009
10
17
269
2809
Atherosclerosis of arteries of extremities
I70.2 [45538421]
—
—
—
—
—
2.3e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.20%
cases:3.94%
controls:0.81%
—
—
—
—
—
6
6
292
3012
11
23
268
2803
Rheumatology
66 [38004491]
1.2e+00
1.3e+00
—
—
—
1.4e+00
7.4e-01
cases:7.57%
controls:2.34%
cases:4.59%
controls:1.28%
—
—
—
—
—
—
cases:4.36%
controls:1.16%
cases:6.09%
controls:3.01%
23
71
281
2963
14
39
291
3005
—
—
—
13
35
285
2983
17
85
262
2741
Limited function/disability (L)
L28 [2002000647]
1.3e+00
2.2e+00
—
—
—
1.4e+00
1.7e+00
cases:2.96%
controls:0.79%
cases:2.30%
controls:0.26%
—
—
—
—
—
—
cases:2.01%
controls:0.50%
cases:8.96%
controls:1.80%
9
24
295
3010
7
8
298
3036
—
—
—
6
15
292
3003
25
51
254
2775
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
—
—
—
—
—
2.3e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.30%
cases:4.66%
controls:1.06%
—
—
—
—
—
9
9
289
3009
13
30
266
2796
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
5.5e-01
—
—
—
—
2.2e+00
1.6e+00
cases:1.64%
controls:0.96%
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.27%
cases:4.30%
controls:0.92%
5
29
299
3005
—
—
—
—
7
8
291
3010
12
26
267
2800
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
1.2e+00
—
—
—
—
2.6e+00
8.1e-01
cases:4.28%
controls:1.35%
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.23%
cases:5.02%
controls:2.30%
13
41
291
2993
—
—
—
—
9
7
289
3011
14
65
265
2761
Inpatient Visit
IP [9201]
2.2e-01
9.0e-01
—
—
2.6e+00
4.6e-01
9.2e-01
cases:3.95%
controls:3.20%
cases:2.62%
controls:1.08%
—
—
—
—
cases:2.62%
controls:0.20%
cases:2.35%
controls:1.49%
cases:11.83%
controls:5.10%
12
97
292
2937
8
33
297
3011
—
—
8
6
297
3036
7
45
291
2973
33
144
246
2682
Laboratory Visit
OMOP4822461 [32036]
7.3e-02
3.4e-01
4.9e-01
2.5e+00
9.2e-01
3.3e-01
1.5e-01
cases:30.59%
controls:29.07%
cases:34.43%
controls:27.20%
cases:13.77%
controls:8.94%
cases:4.92%
controls:0.43%
cases:17.05%
controls:7.56%
cases:38.26%
controls:30.85%
cases:52.69%
controls:49.01%
93
882
211
2152
105
828
200
2216
42
272
263
2772
15
13
290
3031
52
230
253
2812
114
931
184
2087
147
1385
132
1441
Physiotherapy
R4110 [2001310233]
4.0e-01
8.6e-01
—
—
—
2.0e+00
1.4e+00
cases:4.61%
controls:3.13%
cases:3.28%
controls:1.41%
—
—
—
—
—
—
cases:7.72%
controls:1.13%
cases:10.75%
controls:2.90%
14
95
290
2939
10
43
295
3001
—
—
—
23
34
275
2984
30
82
249
2744
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.6e-01
4.5e-01
8.9e-01
—
1.4e+00
5.8e-01
4.9e-01
cases:21.71%
controls:17.57%
cases:20.00%
controls:13.70%
cases:6.23%
controls:2.66%
—
—
cases:7.87%
controls:2.10%
cases:22.82%
controls:14.21%
cases:43.73%
controls:32.31%
66
533
238
2501
61
417
244
2627
19
81
286
2963
—
24
64
281
2978
68
429
230
2589
122
913
157
1913
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
8.6e-02
2.9e-01
5.5e-01
2.3e+00
1.0e+00
4.1e-01
2.4e-01
cases:26.32%
controls:24.69%
cases:25.57%
controls:20.43%
cases:8.20%
controls:4.89%
cases:1.97%
controls:0.20%
cases:9.84%
controls:3.81%
cases:29.87%
controls:22.00%
cases:49.46%
controls:43.42%
80
749
224
2285
78
622
227
2422
25
149
280
2895
6
6
299
3038
30
116
275
2926
89
664
209
2354
138
1227
141
1599
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
8.6e-02
2.9e-01
5.5e-01
2.3e+00
1.0e+00
4.1e-01
2.4e-01
cases:26.32%
controls:24.69%
cases:25.57%
controls:20.43%
cases:8.20%
controls:4.89%
cases:1.97%
controls:0.20%
cases:9.84%
controls:3.81%
cases:29.87%
controls:22.07%
cases:49.46%
controls:43.45%
80
749
224
2285
78
622
227
2422
25
149
280
2895
6
6
299
3038
30
116
275
2926
89
666
209
2352
138
1228
141
1598
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
8.4e-02
2.9e-01
5.4e-01
2.3e+00
1.0e+00
4.0e-01
2.4e-01
cases:26.32%
controls:24.72%
cases:25.57%
controls:20.47%
cases:8.20%
controls:4.93%
cases:1.97%
controls:0.20%
cases:9.84%
controls:3.81%
cases:29.87%
controls:22.17%
cases:49.46%
controls:43.52%
80
750
224
2284
78
623
227
2421
25
150
280
2894
6
6
299
3038
30
116
275
2926
89
669
209
2349
138
1230
141
1596
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
8.6e-02
2.9e-01
5.5e-01
2.3e+00
1.0e+00
4.1e-01
2.4e-01
cases:26.32%
controls:24.69%
cases:25.57%
controls:20.47%
cases:8.20%
controls:4.89%
cases:1.97%
controls:0.20%
cases:9.84%
controls:3.81%
cases:29.87%
controls:22.07%
cases:49.46%
controls:43.42%
80
749
224
2285
78
623
227
2421
25
149
280
2895
6
6
299
3038
30
116
275
2926
89
666
209
2352
138
1227
141
1599
Platelets [#/volume] in Blood
26515-7 [3007461]
8.8e-02
2.8e-01
5.5e-01
2.3e+00
1.0e+00
4.1e-01
2.5e-01
cases:26.32%
controls:24.65%
cases:25.25%
controls:20.40%
cases:8.20%
controls:4.89%
cases:1.97%
controls:0.20%
cases:9.84%
controls:3.81%
cases:29.87%
controls:21.97%
cases:49.46%
controls:43.21%
80
748
224
2286
77
621
228
2423
25
149
280
2895
6
6
299
3038
30
116
275
2926
89
663
209
2355
138
1221
141
1605
Leukocytes [#/volume] in Blood
26464-8 [3010813]
8.4e-02
3.1e-01
5.9e-01
2.3e+00
1.0e+00
4.1e-01
2.4e-01
cases:26.32%
controls:24.72%
cases:25.90%
controls:20.40%
cases:8.52%
controls:4.89%
cases:1.97%
controls:0.20%
cases:9.84%
controls:3.81%
cases:29.87%
controls:22.10%
cases:49.46%
controls:43.49%
80
750
224
2284
79
621
226
2423
26
149
279
2895
6
6
299
3038
30
116
275
2926
89
667
209
2351
138
1229
141
1597
MCH [Entitic mass]
28539-5 [3035941]
8.6e-02
2.9e-01
5.5e-01
2.3e+00
1.0e+00
4.1e-01
2.4e-01
cases:26.32%
controls:24.69%
cases:25.57%
controls:20.43%
cases:8.20%
controls:4.89%
cases:1.97%
controls:0.20%
cases:9.84%
controls:3.81%
cases:29.87%
controls:22.07%
cases:49.46%
controls:43.38%
80
749
224
2285
78
622
227
2422
25
149
280
2895
6
6
299
3038
30
116
275
2926
89
666
209
2352
138
1226
141
1600
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
6.4e-01
—
—
—
—
2.1e+00
1.2e+00
cases:2.96%
controls:1.58%
—
—
—
—
—
—
—
—
cases:4.36%
controls:0.56%
cases:9.32%
controls:2.90%
9
48
295
2986
—
—
—
—
13
17
285
3001
26
82
253
2744
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
9.6e-01
1.2e+00
1.5e+00
—
—
1.1e+00
6.0e-01
cases:13.16%
controls:5.47%
cases:6.56%
controls:2.04%
cases:1.97%
controls:0.46%
—
—
—
—
cases:6.04%
controls:2.02%
cases:10.39%
controls:5.98%
40
166
264
2868
20
62
285
2982
6
14
299
3030
—
—
18
61
280
2957
29
169
250
2657
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.2e+00
2.1e+00
—
—
-1.0e+50
6.7e-01
5.7e-01
cases:4.28%
controls:1.35%
cases:4.59%
controls:0.59%
—
—
—
—
cases:0.00%
controls:0.16%
cases:1.68%
controls:0.86%
cases:4.30%
controls:2.48%
13
41
291
2993
14
18
291
3026
—
—
0
5
305
3037
5
26
293
2992
12
70
267
2756
Case Management Agency
251B00000X [38004193]
1.3e-01
3.3e-01
2.7e-01
3.2e+00
4.3e-01
3.3e-01
9.3e-02
cases:52.63%
controls:49.47%
cases:51.15%
controls:43.00%
cases:20.66%
controls:16.59%
cases:20.66%
controls:1.02%
cases:23.28%
controls:16.44%
cases:54.36%
controls:46.12%
cases:72.76%
controls:70.88%
160
1501
144
1533
156
1309
149
1735
63
505
242
2539
63
31
242
3013
71
500
234
2542
162
1392
136
1626
203
2003
76
823
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4.5e-01
1.1e+00
8.5e-01
—
1.6e+00
3.4e-01
5.1e-01
cases:15.13%
controls:10.25%
cases:14.10%
controls:5.29%
cases:1.97%
controls:0.85%
—
—
cases:2.62%
controls:0.53%
cases:8.72%
controls:6.36%
cases:24.73%
controls:16.42%
46
311
258
2723
43
161
262
2883
6
26
299
3018
—
8
16
297
3026
26
192
272
2826
69
464
210
2362
tizanidine; oral
M03BX02 [21604116]
3.5e-01
6.5e-01
—
—
1.7e+00
9.1e-01
5.6e-01
cases:19.74%
controls:14.77%
cases:8.52%
controls:4.63%
—
—
—
—
cases:2.95%
controls:0.53%
cases:8.05%
controls:3.41%
cases:20.79%
controls:13.06%
60
448
244
2586
26
141
279
2903
—
—
9
16
296
3026
24
103
274
2915
58
369
221
2457
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
1.1e+00
1.1e+00
—
—
—
2.1e+00
7.9e-01
cases:7.89%
controls:2.80%
cases:1.97%
controls:0.66%
—
—
—
—
—
—
cases:4.70%
controls:0.60%
cases:6.81%
controls:3.22%
24
85
280
2949
6
20
299
3024
—
—
—
14
18
284
3000
19
91
260
2735
Pulmonary Disease
29 [38004472]
7.1e-01
6.5e-01
—
—
-1.0e+50
1.0e+00
1.4e+00
cases:11.51%
controls:6.00%
cases:5.57%
controls:2.99%
—
—
—
—
cases:0.00%
controls:0.69%
cases:8.05%
controls:3.05%
cases:22.58%
controls:6.55%
35
182
269
2852
17
91
288
2953
—
—
0
21
305
3021
24
92
274
2926
63
185
216
2641
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
7.3e-01
—
—
—
—
1.8e+00
1.3e+00
cases:2.63%
controls:1.29%
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.40%
cases:6.09%
controls:1.73%
8
39
296
2995
—
—
—
—
7
12
291
3006
17
49
262
2777
Inpatient Hospital
21 [8717]
6.0e-01
7.9e-01
6.3e-01
—
1.2e+00
8.9e-01
8.2e-01
cases:39.47%
controls:26.43%
cases:18.36%
controls:9.30%
cases:2.62%
controls:1.41%
—
—
cases:3.61%
controls:1.12%
cases:17.45%
controls:7.95%
cases:39.07%
controls:22.08%
120
802
184
2232
56
283
249
2761
8
43
297
3001
—
11
34
294
3008
52
240
246
2778
109
624
170
2202
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
5.3e-01
8.5e-01
—
—
2.0e+00
7.9e-01
1.0e+00
cases:6.91%
controls:4.19%
cases:6.23%
controls:2.76%
—
—
—
—
cases:2.62%
controls:0.36%
cases:5.37%
controls:2.52%
cases:17.92%
controls:7.11%
21
127
283
2907
19
84
286
2960
—
—
8
11
297
3031
16
76
282
2942
50
201
229
2625
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
—
—
—
—
—
1.7e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:4.36%
controls:0.86%
cases:8.60%
controls:2.30%
—
—
—
—
—
13
26
285
2992
24
65
255
2761
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
1.9e-01
3.4e-01
5.9e-01
—
1.5e+00
6.6e-01
7.0e-01
cases:12.83%
controls:10.84%
cases:10.16%
controls:7.42%
cases:3.28%
controls:1.84%
—
—
cases:4.92%
controls:1.12%
cases:13.09%
controls:7.19%
cases:29.75%
controls:17.41%
39
329
265
2705
31
226
274
2818
10
56
295
2988
—
15
34
290
3008
39
217
259
2801
83
492
196
2334
12 lead EKG panel
34534-8 [3044889]
1.8e-01
5.7e-01
1.4e+00
—
2.3e+00
6.6e-01
5.2e-01
cases:10.20%
controls:8.64%
cases:8.85%
controls:5.22%
cases:2.30%
controls:0.59%
—
—
cases:2.95%
controls:0.30%
cases:10.40%
controls:5.67%
cases:24.73%
controls:16.38%
31
262
273
2772
27
159
278
2885
7
18
298
3026
—
9
9
296
3033
31
171
267
2847
69
463
210
2363
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.5e-01
5.7e-01
7.2e-01
—
1.1e+00
5.8e-01
4.7e-01
cases:24.34%
controls:18.42%
cases:19.02%
controls:11.70%
cases:5.57%
controls:2.79%
—
—
cases:5.57%
controls:1.84%
cases:20.81%
controls:12.82%
cases:42.29%
controls:31.35%
74
559
230
2475
58
356
247
2688
17
85
288
2959
—
17
56
288
2986
62
387
236
2631
118
886
161
1940
Emergency Room Visit
ER [9203]
5.1e-01
7.5e-01
6.5e-01
1.0e+50
1.2e+00
6.5e-01
8.3e-01
cases:41.45%
controls:29.73%
cases:19.02%
controls:9.95%
cases:2.30%
controls:1.22%
cases:3.28%
controls:0.00%
cases:3.61%
controls:1.15%
cases:15.77%
controls:8.88%
cases:44.09%
controls:25.65%
126
902
178
2132
58
303
247
2741
7
37
298
3007
10
0
295
3044
11
35
294
3007
47
268
251
2750
123
725
156
2101
Other spondylosis with radiculopathy
M47.2 [45591850]
1.4e+00
2.7e+00
—
—
—
—
—
cases:1.64%
controls:0.40%
cases:2.30%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
5
12
299
3022
7
5
298
3039
—
—
—
—
—
Internal Medicine
11 [38004456]
3.3e-01
9.6e-01
7.8e-01
1.0e+50
9.9e-01
8.4e-01
8.3e-01
cases:21.38%
controls:16.32%
cases:15.74%
controls:6.67%
cases:2.95%
controls:1.38%
cases:2.95%
controls:0.00%
cases:3.28%
controls:1.25%
cases:14.09%
controls:6.59%
cases:28.67%
controls:14.86%
65
495
239
2539
48
203
257
2841
9
42
296
3002
9
0
296
3044
10
38
295
3004
42
199
256
2819
80
420
199
2406
More than one and less than three hours
ZXE10 [2001311401]
1.5e-01
1.2e+00
—
—
—
1.1e+00
1.4e+00
cases:5.59%
controls:4.85%
cases:4.26%
controls:1.28%
—
—
—
—
—
—
cases:3.02%
controls:1.06%
cases:10.39%
controls:2.87%
17
147
287
2887
13
39
292
3005
—
—
—
9
32
289
2986
29
81
250
2745
One hour or less
ZXE00 [2001311394]
8.2e-02
1.5e+00
—
—
—
8.7e-01
1.1e+00
cases:5.59%
controls:5.17%
cases:4.59%
controls:1.08%
—
—
—
—
—
—
cases:3.02%
controls:1.29%
cases:11.11%
controls:3.96%
17
157
287
2877
14
33
291
3011
—
—
—
9
39
289
2979
31
112
248
2714
Basophils/Leukocytes in Blood
30180-4 [3022096]
4.2e-01
2.4e-01
8.9e-01
—
1.7e+00
4.4e-01
8.1e-01
cases:8.88%
controls:6.03%
cases:4.92%
controls:3.91%
cases:2.30%
controls:0.95%
—
—
cases:2.95%
controls:0.56%
cases:5.70%
controls:3.74%
cases:19.00%
controls:9.48%
27
183
277
2851
15
119
290
2925
7
29
298
3015
—
9
17
296
3025
17
113
281
2905
53
268
226
2558
baclofen; oral, parenteral
M03BX01 [21604115]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.51%
controls:0.21%
—
—
—
—
—
—
7
6
272
2820
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
4.2e-01
2.3e-01
8.9e-01
—
1.7e+00
4.4e-01
7.9e-01
cases:8.88%
controls:6.03%
cases:4.92%
controls:3.94%
cases:2.30%
controls:0.95%
—
—
cases:2.95%
controls:0.56%
cases:5.70%
controls:3.74%
cases:18.64%
controls:9.38%
27
183
277
2851
15
120
290
2924
7
29
298
3015
—
9
17
296
3025
17
113
281
2905
52
265
227
2561
Monocytes/Leukocytes in Blood
26485-3 [3019069]
4.9e-01
2.3e-01
8.9e-01
—
1.7e+00
4.9e-01
7.9e-01
cases:9.54%
controls:6.06%
cases:4.92%
controls:3.94%
cases:2.30%
controls:0.95%
—
—
cases:2.95%
controls:0.56%
cases:6.04%
controls:3.78%
cases:18.64%
controls:9.45%
29
184
275
2850
15
120
290
2924
7
29
298
3015
—
9
17
296
3025
18
114
280
2904
52
267
227
2559
After-cataract
H26.4 [45600893]
2.0e+00
—
—
—
—
—
2.4e+00
cases:1.64%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.35%
5
7
299
3027
—
—
—
—
—
11
10
268
2816
Neuropsychological investigation
XA800 [2001300412]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.35%
—
—
—
—
—
—
11
10
268
2816
Eosinophils [#/volume] in Blood
26449-9 [3013115]
5.1e-01
2.3e-01
9.0e-01
—
1.7e+00
5.1e-01
6.9e-01
cases:11.18%
controls:7.05%
cases:5.90%
controls:4.73%
cases:2.62%
controls:1.08%
—
—
cases:3.28%
controls:0.59%
cases:6.71%
controls:4.14%
cases:19.71%
controls:11.00%
34
214
270
2820
18
144
287
2900
8
33
297
3011
—
10
18
295
3024
20
125
278
2893
55
311
224
2515
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
4.9e-01
3.0e-01
8.3e-01
—
1.7e+00
4.1e-01
7.2e-01
cases:9.87%
controls:6.26%
cases:5.25%
controls:3.94%
cases:2.30%
controls:1.02%
—
—
cases:2.95%
controls:0.56%
cases:6.04%
controls:4.11%
cases:18.64%
controls:10.05%
30
190
274
2844
16
120
289
2924
7
31
298
3013
—
9
17
296
3025
18
124
280
2894
52
284
227
2542
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.5e-01
4.2e-01
8.8e-01
—
1.4e+00
5.2e-01
4.7e-01
cases:21.71%
controls:17.83%
cases:19.67%
controls:13.83%
cases:6.23%
controls:2.69%
—
—
cases:8.20%
controls:2.14%
cases:22.15%
controls:14.45%
cases:43.73%
controls:32.70%
66
541
238
2493
60
421
245
2623
19
82
286
2962
—
25
65
280
2977
66
436
232
2582
122
924
157
1902
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
4.8e-01
3.4e-01
8.9e-01
—
1.7e+00
3.0e-01
6.5e-01
cases:9.54%
controls:6.13%
cases:5.25%
controls:3.78%
cases:2.30%
controls:0.95%
—
—
cases:2.95%
controls:0.53%
cases:5.37%
controls:4.04%
cases:17.20%
controls:9.80%
29
186
275
2848
16
115
289
2929
7
29
298
3015
—
9
16
296
3026
16
122
282
2896
48
277
231
2549
Monocytes [#/volume] in Blood
26484-6 [3001604]
5.3e-01
1.8e-01
9.3e-01
—
1.7e+00
4.6e-01
6.9e-01
cases:10.53%
controls:6.49%
cases:5.25%
controls:4.43%
cases:2.62%
controls:1.05%
—
—
cases:2.95%
controls:0.56%
cases:6.38%
controls:4.11%
cases:19.00%
controls:10.54%
32
197
272
2837
16
135
289
2909
8
32
297
3012
—
9
17
296
3025
19
124
279
2894
53
298
226
2528
Basophils [#/volume] in Blood
26444-0 [3006315]
5.3e-01
1.7e-01
9.3e-01
—
1.7e+00
4.6e-01
6.8e-01
cases:10.53%
controls:6.49%
cases:5.25%
controls:4.47%
cases:2.62%
controls:1.05%
—
—
cases:2.95%
controls:0.56%
cases:6.38%
controls:4.11%
cases:19.00%
controls:10.58%
32
197
272
2837
16
136
289
2908
8
32
297
3012
—
9
17
296
3025
19
124
279
2894
53
299
226
2527
Reaction to severe stress, unspecified
F43.9 [45552484]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.87%
controls:0.28%
—
—
—
—
—
—
8
8
271
2818
Senile nuclear cataract
H25.1 [45581628]
9.3e-01
1.7e+00
—
—
—
2.3e+00
6.2e-01
cases:2.96%
controls:1.19%
cases:1.97%
controls:0.36%
—
—
—
—
—
—
cases:2.68%
controls:0.27%
cases:3.23%
controls:1.77%
9
36
295
2998
6
11
299
3033
—
—
—
8
8
290
3010
9
50
270
2776
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
5.2e-01
2.1e-01
8.7e-01
—
1.7e+00
3.7e-01
6.5e-01
cases:10.86%
controls:6.72%
cases:5.57%
controls:4.57%
cases:2.62%
controls:1.12%
—
—
cases:2.95%
controls:0.56%
cases:6.38%
controls:4.47%
cases:19.00%
controls:10.90%
33
204
271
2830
17
139
288
2905
8
34
297
3010
—
9
17
296
3025
19
135
279
2883
53
308
226
2518
Fitting and adjustment of other specified devices
Z46.8 [45581035]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.15%
controls:0.21%
—
—
—
—
—
—
6
6
273
2820
flumetasone and antiinfectives
S02CA02 [21605174]
8.3e-01
—
—
—
—
2.3e+00
—
cases:1.64%
controls:0.73%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.20%
—
—
5
22
299
3012
—
—
—
—
6
6
292
3012
—
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
—
—
—
—
—
2.0e+00
2.3e+00
—
—
—
—
—
—
—
—
—
—
cases:1.68%
controls:0.23%
cases:1.79%
controls:0.18%
—
—
—
—
—
5
7
293
3011
5
5
274
2821
Pediatric Cardiology
OMOP4821938 [45756805]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.18%
—
—
—
—
—
—
5
5
274
2821
Assessment of need for aid
SPAT1229 [2001700330]
—
—
—
—
—
2.3e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:1.68%
controls:0.17%
cases:2.51%
controls:0.67%
—
—
—
—
—
5
5
293
3013
7
19
272
2807
Trochanteric bursitis
M70.6 [45606304]
8.3e-01
—
—
—
—
2.3e+00
8.9e-01
cases:1.64%
controls:0.73%
—
—
—
—
—
—
—
—
cases:1.68%
controls:0.17%
cases:2.87%
controls:1.20%
5
22
299
3012
—
—
—
—
5
5
293
3013
8
34
271
2792
ezetimibe; oral
C10AX09 [21601896]
9.3e-01
1.3e+00
—
—
—
1.3e+00
1.0e+00
cases:2.63%
controls:1.05%
cases:3.28%
controls:0.92%
—
—
—
—
—
—
cases:4.03%
controls:1.16%
cases:5.73%
controls:2.09%
8
32
296
3002
10
28
295
3016
—
—
—
12
35
286
2983
16
59
263
2767
Medical doctor
Z2221 [2001311556]
4.3e-01
1.1e+00
—
—
—
1.3e+00
9.6e-01
cases:6.91%
controls:4.61%
cases:3.93%
controls:1.35%
—
—
—
—
—
—
cases:5.03%
controls:1.36%
cases:7.53%
controls:3.01%
21
140
283
2894
12
41
293
3003
—
—
—
15
41
283
2977
21
85
258
2741
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.3e-01
5.6e-01
3.3e-02
—
1.1e+00
5.8e-01
4.0e-01
cases:30.59%
controls:24.13%
cases:20.00%
controls:12.55%
cases:1.97%
controls:1.91%
—
—
cases:6.23%
controls:2.10%
cases:20.47%
controls:12.56%
cases:42.65%
controls:33.37%
93
732
211
2302
61
382
244
2662
6
58
299
2986
—
19
64
286
2978
61
379
237
2639
119
943
160
1883
FEV1
20150-9 [3024653]
9.9e-01
—
—
—
—
1.6e+00
2.2e+00
cases:3.29%
controls:1.25%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.40%
cases:5.73%
controls:0.64%
10
38
294
2996
—
—
—
—
6
12
292
3006
16
18
263
2808
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
9.9e-01
—
—
—
—
1.6e+00
2.2e+00
cases:3.29%
controls:1.25%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.40%
cases:5.73%
controls:0.64%
10
38
294
2996
—
—
—
—
6
12
292
3006
16
18
263
2808
FEV1/FVC
19926-5 [3011505]
9.9e-01
—
—
—
—
1.6e+00
2.2e+00
cases:3.29%
controls:1.25%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.40%
cases:5.73%
controls:0.64%
10
38
294
2996
—
—
—
—
6
12
292
3006
16
18
263
2808
Social worker
Z2446 [2001311559]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.87%
controls:0.32%
—
—
—
—
—
—
8
9
271
2817
Musculoskeletal disease other
L99 [2002000718]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.51%
controls:0.28%
—
—
—
—
—
—
7
8
272
2818
Thorax X-ray examination
GD1AA [2001303617]
3.9e-01
4.0e-01
—
—
—
1.1e+00
1.1e+00
cases:6.25%
controls:4.32%
cases:2.95%
controls:2.00%
—
—
—
—
—
—
cases:5.03%
controls:1.72%
cases:14.34%
controls:5.31%
19
131
285
2903
9
61
296
2983
—
—
—
15
52
283
2966
40
150
239
2676
FEV1 --post bronchodilation
20155-8 [3023550]
1.1e+00
—
—
—
—
—
2.2e+00
cases:3.29%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.64%
10
34
294
3000
—
—
—
—
—
15
18
264
2808
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.1e+00
—
—
—
—
—
2.2e+00
cases:3.29%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.64%
10
34
294
3000
—
—
—
—
—
15
18
264
2808
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.1e+00
—
—
—
—
—
2.2e+00
cases:3.29%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.64%
10
34
294
3000
—
—
—
—
—
15
18
264
2808
FVC percent change Respiratory system
69982-7 [42868471]
1.1e+00
—
—
—
—
—
2.2e+00
cases:3.29%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.64%
10
34
294
3000
—
—
—
—
—
15
18
264
2808
FEV1 percent change
69983-5 [42868472]
1.1e+00
—
—
—
—
—
2.2e+00
cases:3.29%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:0.64%
10
34
294
3000
—
—
—
—
—
15
18
264
2808
Presence of electronic cardiac devices
Z95.0 [45571406]
-1.0e+50
—
—
—
—
—
2.2e+00
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:2.15%
controls:0.25%
0
6
304
3028
—
—
—
—
—
6
7
273
2819
General symptom/complaint other
A29 [2002000163]
—
-1.0e+50
—
—
—
2.2e+00
6.8e-01
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:2.01%
controls:0.23%
cases:2.15%
controls:1.10%
—
0
10
305
3034
—
—
—
6
7
292
3011
6
31
273
2795
Asthma, unspecified
J45.9 [45562456]
9.6e-01
1.1e+00
—
—
—
9.2e-01
1.2e+00
cases:5.59%
controls:2.21%
cases:2.30%
controls:0.76%
—
—
—
—
—
—
cases:3.02%
controls:1.23%
cases:7.89%
controls:2.55%
17
67
287
2967
7
23
298
3021
—
—
—
9
37
289
2981
22
72
257
2754
Psychosocial counselling and guidance
SPAT1307 [2001700408]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.39%
—
—
—
—
—
—
9
11
270
2815
Acute sinusitis, unspecified
J01.9 [45543252]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.51%
controls:0.32%
—
—
—
—
—
—
7
9
272
2817
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.1e-01
1.2e-01
8.4e-01
—
1.5e+00
3.9e-01
6.1e-01
cases:11.51%
controls:7.98%
cases:6.23%
controls:5.58%
cases:3.28%
controls:1.45%
—
—
cases:3.61%
controls:0.85%
cases:7.05%
controls:4.90%
cases:20.07%
controls:12.00%
35
242
269
2792
19
170
286
2874
10
44
295
3000
—
11
26
294
3016
21
148
277
2870
56
339
223
2487
Scheduled procedure
ZXD10 [2001311387]
3.3e-01
1.1e+00
—
—
—
9.5e-01
9.7e-01
cases:6.91%
controls:5.08%
cases:4.59%
controls:1.61%
—
—
—
—
—
—
cases:3.02%
controls:1.19%
cases:8.60%
controls:3.43%
21
154
283
2880
14
49
291
2995
—
—
—
9
36
289
2982
24
97
255
2729
Check up of cardiac pacemaker
XFP20 [2001303367]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.15%
controls:0.28%
—
—
—
—
—
—
6
8
273
2818
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
-1.0e+50
—
—
—
—
2.0e+00
9.4e-01
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.27%
cases:4.66%
controls:1.88%
0
23
304
3011
—
—
—
—
6
8
292
3010
13
53
266
2773
Bilateral
ZXA10 [2001311348]
4.7e-01
—
—
—
—
2.0e+00
1.0e+00
cases:2.30%
controls:1.45%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.27%
cases:3.58%
controls:1.31%
7
44
297
2990
—
—
—
—
6
8
292
3010
10
37
269
2789
Myalgia
M79.1 [45587062]
1.3e+00
2.0e+00
—
—
—
—
7.3e-01
cases:2.63%
controls:0.73%
cases:2.95%
controls:0.39%
—
—
—
—
—
—
—
—
cases:4.66%
controls:2.30%
8
22
296
3012
9
12
296
3032
—
—
—
—
13
65
266
2761
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.2e-01
3.4e-01
7.1e-01
—
1.4e+00
6.0e-01
2.9e-01
cases:17.76%
controls:14.83%
cases:16.72%
controls:12.45%
cases:5.90%
controls:2.99%
—
—
cases:7.87%
controls:2.07%
cases:21.14%
controls:12.82%
cases:34.05%
controls:27.88%
54
450
250
2584
51
379
254
2665
18
91
287
2953
—
24
63
281
2979
63
387
235
2631
95
788
184
2038
Presence of intraocular lens
Z96.1 [45585885]
2.0e+00
—
—
—
—
—
1.1e+00
cases:2.30%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.06%
7
10
297
3024
—
—
—
—
—
9
30
270
2796
Ophthalmology
18 [38004463]
4.3e-01
5.5e-01
—
—
1.0e+00
1.2e+00
7.3e-01
cases:14.14%
controls:9.69%
cases:7.21%
controls:4.30%
—
—
—
—
cases:1.97%
controls:0.72%
cases:12.75%
controls:4.17%
cases:21.51%
controls:11.64%
43
294
261
2740
22
131
283
2913
—
—
6
22
299
3020
38
126
260
2892
60
329
219
2497
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
1.3e+00
—
—
—
—
—
1.9e+00
cases:1.97%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:2.51%
controls:0.39%
6
17
298
3017
—
—
—
—
—
7
11
272
2815
nifedipine; oral, parenteral
C08CA05 [21601751]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.51%
controls:0.39%
—
—
—
—
—
—
7
11
272
2815
Dental caries
K02 [45552906]
1.9e+00
—
—
—
—
—
—
cases:2.96%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
9
14
295
3020
—
—
—
—
—
—
lamotrigine; oral
N03AX09 [21604431]
1.6e+00
1.6e+00
—
—
—
1.7e+00
1.9e+00
cases:2.63%
controls:0.56%
cases:2.62%
controls:0.56%
—
—
—
—
—
—
cases:2.35%
controls:0.43%
cases:3.94%
controls:0.64%
8
17
296
3017
8
17
297
3027
—
—
—
7
13
291
3005
11
18
268
2808
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
4.7e-01
6.2e-01
1.1e+00
—
1.8e+00
6.3e-01
6.2e-01
cases:6.58%
controls:4.22%
cases:4.59%
controls:2.53%
cases:1.64%
controls:0.53%
—
—
cases:2.62%
controls:0.43%
cases:5.03%
controls:2.75%
cases:12.54%
controls:7.15%
20
128
284
2906
14
77
291
2967
5
16
300
3028
—
8
13
297
3029
15
83
283
2935
35
202
244
2624
hydroxocobalamin
V03AB33 [21605256]
—
1.2e+00
—
—
—
1.3e+00
1.8e+00
—
—
cases:1.64%
controls:0.49%
—
—
—
—
—
—
cases:1.68%
controls:0.46%
cases:3.23%
controls:0.53%
—
5
15
300
3029
—
—
—
5
14
293
3004
9
15
270
2811
hydroxocobalamin; parenteral
B03BA03 [21601123]
—
1.2e+00
—
—
—
1.3e+00
1.8e+00
—
—
cases:1.64%
controls:0.49%
—
—
—
—
—
—
cases:1.68%
controls:0.46%
cases:3.23%
controls:0.53%
—
5
15
300
3029
—
—
—
5
14
293
3004
9
15
270
2811
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
4.2e-01
1.1e+00
—
—
—
1.8e+00
7.7e-01
cases:1.64%
controls:1.09%
cases:1.97%
controls:0.69%
—
—
—
—
—
—
cases:2.35%
controls:0.40%
cases:2.87%
controls:1.34%
5
33
299
3001
6
21
299
3023
—
—
—
7
12
291
3006
8
38
271
2788
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
2.0e-01
5.6e-01
7.7e-01
—
1.2e+00
4.7e-01
4.3e-01
cases:18.09%
controls:15.33%
cases:16.39%
controls:10.09%
cases:3.28%
controls:1.54%
—
—
cases:3.93%
controls:1.18%
cases:15.10%
controls:10.04%
cases:36.92%
controls:27.60%
55
465
249
2569
50
307
255
2737
10
47
295
2997
—
12
36
293
3006
45
303
253
2715
103
780
176
2046
diclofenac
D11AX18 [21602355]
4.5e-01
8.7e-01
—
—
—
1.8e+00
5.1e-01
cases:2.96%
controls:1.91%
cases:1.64%
controls:0.69%
—
—
—
—
—
—
cases:2.68%
controls:0.46%
cases:3.58%
controls:2.19%
9
58
295
2976
5
21
300
3023
—
—
—
8
14
290
3004
10
62
269
2764
diclofenac; ointment
M02AA15 [21604051]
4.5e-01
8.7e-01
—
—
—
1.8e+00
5.1e-01
cases:2.96%
controls:1.91%
cases:1.64%
controls:0.69%
—
—
—
—
—
—
cases:2.68%
controls:0.46%
cases:3.58%
controls:2.19%
9
58
295
2976
5
21
300
3023
—
—
—
8
14
290
3004
10
62
269
2764
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.4e-01
3.0e-01
5.2e-01
—
1.3e+00
5.1e-01
3.1e-01
cases:21.38%
controls:19.12%
cases:19.67%
controls:15.34%
cases:5.57%
controls:3.38%
—
—
cases:8.20%
controls:2.47%
cases:23.83%
controls:15.87%
cases:43.73%
controls:36.20%
65
580
239
2454
60
467
245
2577
17
103
288
2941
—
25
75
280
2967
71
479
227
2539
122
1023
157
1803
Intravenous
ZX120 [2001311495]
—
-1.0e+50
—
—
—
—
1.7e+00
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.60%
—
0
9
305
3035
—
—
—
—
9
17
270
2809
mirtazapine; oral
N06AX11 [21604740]
8.5e-01
5.7e-01
1.3e+00
—
—
6.5e-01
8.2e-01
cases:10.86%
controls:4.94%
cases:3.93%
controls:2.27%
cases:1.64%
controls:0.46%
—
—
—
—
cases:4.70%
controls:2.52%
cases:13.62%
controls:6.51%
33
150
271
2884
12
69
293
2975
5
14
300
3030
—
—
14
76
284
2942
38
184
241
2642
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
6.9e-01
5.6e-01
—
—
—
6.8e-01
9.4e-01
cases:11.84%
controls:6.33%
cases:3.61%
controls:2.10%
—
—
—
—
—
—
cases:4.03%
controls:2.09%
cases:13.26%
controls:5.63%
36
192
268
2842
11
64
294
2980
—
—
—
12
63
286
2955
37
159
242
2667
Gastroenterology
10 [38004455]
8.5e-01
5.4e-01
-1.0e+50
—
—
7.3e-02
7.7e-01
cases:7.24%
controls:3.23%
cases:3.61%
controls:2.14%
cases:0.00%
controls:0.49%
—
—
—
—
cases:2.35%
controls:2.19%
cases:10.75%
controls:5.27%
22
98
282
2936
11
65
294
2979
0
15
305
3029
—
—
7
66
291
2952
30
149
249
2677
Otolaryngology
4 [38004449]
8.0e-01
5.6e-01
—
—
—
4.5e-01
8.1e-01
cases:17.11%
controls:8.50%
cases:5.25%
controls:3.06%
—
—
—
—
—
—
cases:4.70%
controls:3.05%
cases:17.20%
controls:8.46%
52
258
252
2776
16
93
289
2951
—
—
—
14
92
284
2926
48
239
231
2587
Heart failure, unspecified
I50.9 [45576879]
-1.0e+50
—
—
—
—
—
1.6e+00
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:3.58%
controls:0.74%
0
13
304
3021
—
—
—
—
—
10
21
269
2805
Differential panel, method unspecified - Blood
69738-3 [42870588]
8.0e-01
1.8e-01
9.7e-01
—
1.6e+00
7.3e-01
8.0e-01
cases:7.89%
controls:3.72%
cases:3.28%
controls:2.76%
cases:1.97%
controls:0.76%
—
—
cases:2.30%
controls:0.46%
cases:5.03%
controls:2.49%
cases:12.54%
controls:6.05%
24
113
280
2921
10
84
295
2960
6
23
299
3021
—
7
14
298
3028
15
75
283
2943
35
171
244
2655
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
7.1e-01
1.6e+00
—
—
—
7.6e-01
1.9e-01
cases:4.28%
controls:2.14%
cases:3.28%
controls:0.69%
—
—
—
—
—
—
cases:1.68%
controls:0.80%
cases:4.30%
controls:3.57%
13
65
291
2969
10
21
295
3023
—
—
—
5
24
293
2994
12
101
267
2725
Intravenous general anesthesia
WX404 [2001310807]
-8.6e-02
—
—
—
—
—
1.6e+00
cases:2.30%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
cases:6.09%
controls:1.34%
7
76
297
2958
—
—
—
—
—
17
38
262
2788
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
7.9e-01
—
—
—
-1.0e+50
-1.0e+50
1.5e+00
cases:2.30%
controls:1.05%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.46%
cases:4.66%
controls:1.03%
7
32
297
3002
—
—
—
0
5
305
3037
0
14
298
3004
13
29
266
2797
nortriptyline; oral, parenteral
N06AA10 [21604697]
1.3e+00
1.3e+00
—
—
—
1.9e+00
1.5e+00
cases:1.97%
controls:0.53%
cases:1.64%
controls:0.46%
—
—
—
—
—
—
cases:1.68%
controls:0.27%
cases:3.23%
controls:0.71%
6
16
298
3018
5
14
300
3030
—
—
—
5
8
293
3010
9
20
270
2806
salbutamol; inhalant
R03AC02 [21603256]
7.9e-01
3.8e-01
—
—
9.3e-01
6.3e-01
7.4e-01
cases:22.70%
controls:11.77%
cases:9.18%
controls:6.47%
—
—
—
—
cases:1.97%
controls:0.79%
cases:11.74%
controls:6.63%
cases:27.60%
controls:15.39%
69
357
235
2677
28
197
277
2847
—
—
6
24
299
3018
35
200
263
2818
77
435
202
2391
Concussion
S06.0 [45582805]
—
-1.0e+50
—
—
—
-1.0e+50
1.5e+00
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:0.00%
controls:0.17%
cases:3.94%
controls:0.88%
—
0
10
305
3034
—
—
—
0
5
298
3013
11
25
268
2801
Examination of ears and hearing
Z01.1 [45547279]
1.5e+00
—
—
—
—
—
8.6e-01
cases:2.96%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
cases:2.87%
controls:1.24%
9
20
295
3014
—
—
—
—
—
8
35
271
2791
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
6.7e-01
1.5e+00
—
—
-1.0e+50
—
7.1e-01
cases:3.62%
controls:1.88%
cases:2.95%
controls:0.66%
—
—
—
—
cases:0.00%
controls:0.16%
—
—
cases:3.94%
controls:1.98%
11
57
293
2977
9
20
296
3024
—
—
0
5
305
3037
—
11
56
268
2770
More than three and less than five hours
ZXE20 [2001311408]
—
-1.0e+50
—
—
—
-1.0e+50
1.5e+00
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.17%
cases:3.58%
controls:0.81%
—
0
16
305
3028
—
—
—
0
5
298
3013
10
23
269
2803
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
4.5e-01
—
—
—
—
—
1.5e+00
cases:1.64%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.74%
5
32
299
3002
—
—
—
—
—
9
21
270
2805
potassium chloride; oral
A12BA01 [21600877]
-1.0e+50
-1.0e+50
—
—
—
—
1.5e+00
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.92%
0
15
304
3019
0
15
305
3029
—
—
—
—
11
26
268
2800
Mixed anxiety and depressive disorder
F41.2 [45566845]
1.5e+00
—
—
—
—
—
1.4e+00
cases:2.30%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:6.09%
controls:1.52%
7
16
297
3018
—
—
—
—
—
17
43
262
2783
formoterol and budesonide
R03AK07 [21603281]
1.4e+00
1.6e+00
-1.0e+50
—
—
1.6e+00
6.5e-01
cases:4.61%
controls:1.15%
cases:1.97%
controls:0.39%
cases:0.00%
controls:0.16%
—
—
—
—
cases:2.01%
controls:0.43%
cases:3.58%
controls:1.91%
14
35
290
2999
6
12
299
3032
0
5
305
3039
—
—
6
13
292
3005
10
54
269
2772
ECG with 12 standard connections
XF400 [2001303368]
4.1e-01
—
—
—
—
—
1.4e+00
cases:1.97%
controls:1.32%
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:0.99%
6
40
298
2994
—
—
—
—
—
11
28
268
2798
Dyspnoea
R06.0 [45558449]
3.0e-01
—
—
—
—
1.2e+00
1.4e+00
cases:2.96%
controls:2.21%
—
—
—
—
—
—
—
—
cases:1.68%
controls:0.50%
cases:9.68%
controls:2.58%
9
67
295
2967
—
—
—
—
5
15
293
3003
27
73
252
2753
Hearing complaint
H02 [2002000476]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.58%
controls:0.92%
—
—
—
—
—
—
10
26
269
2800
Examination of eyes and vision
Z01.0 [45566391]
4.3e-02
8.3e-01
—
—
—
1.4e+00
7.8e-01
cases:2.30%
controls:2.21%
cases:1.64%
controls:0.72%
—
—
—
—
—
—
cases:3.36%
controls:0.86%
cases:4.30%
controls:2.02%
7
67
297
2967
5
22
300
3022
—
—
—
10
26
288
2992
12
57
267
2769
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
—
—
—
—
—
1.5e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.46%
cases:4.66%
controls:1.24%
—
—
—
—
—
6
14
292
3004
13
35
266
2791
Pneumonia, unspecified
J18.9 [45601123]
8.7e-02
—
—
—
—
—
1.3e+00
cases:1.97%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
cases:6.81%
controls:1.88%
6
55
298
2979
—
—
—
—
—
19
53
260
2773
Gas panel - Venous blood
24339-4 [3000991]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.30%
controls:1.20%
—
—
—
—
—
—
12
34
267
2792
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.02%
controls:1.45%
—
—
—
—
—
—
14
41
265
2785
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.02%
controls:1.45%
—
—
—
—
—
—
14
41
265
2785
pH of Arterial blood
2744-1 [3019977]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.02%
controls:1.45%
—
—
—
—
—
—
14
41
265
2785
Outpatient Hospital
22 [8756]
5.6e-01
4.6e-01
7.9e-01
—
9.7e-01
6.1e-01
7.2e-01
cases:30.59%
controls:20.14%
cases:10.49%
controls:6.90%
cases:2.30%
controls:1.05%
—
—
cases:1.97%
controls:0.76%
cases:9.73%
controls:5.53%
cases:28.32%
controls:16.17%
93
611
211
2423
32
210
273
2834
7
32
298
3012
—
6
23
299
3019
29
167
269
2851
79
457
200
2369
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
7.3e-01
—
—
—
—
—
1.3e+00
cases:2.30%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:1.59%
7
34
297
3000
—
—
—
—
—
15
45
264
2781
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.5e-01
3.7e-01
7.1e-01
—
1.3e+00
4.0e-01
3.1e-01
cases:22.70%
controls:20.17%
cases:22.30%
controls:16.56%
cases:7.54%
controls:3.84%
—
—
cases:9.84%
controls:3.02%
cases:24.16%
controls:17.59%
cases:44.80%
controls:37.26%
69
612
235
2422
68
504
237
2540
23
117
282
2927
—
30
92
275
2950
72
531
226
2487
125
1053
154
1773
Telehealth
OMOP5556618 [722455]
2.1e-01
6.2e-01
—
—
3.8e-01
4.6e-01
6.3e-01
cases:22.04%
controls:18.66%
cases:13.77%
controls:7.88%
—
—
—
—
cases:1.97%
controls:1.35%
cases:11.41%
controls:7.52%
cases:30.82%
controls:19.21%
67
566
237
2468
42
240
263
2804
—
—
6
41
299
3001
34
227
264
2791
86
543
193
2283
Ankle symptom/complaint
L16 [2002000640]
—
-1.0e+50
—
—
—
-1.0e+50
1.2e+00
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:4.30%
controls:1.27%
—
0
6
305
3038
—
—
—
0
11
298
3007
12
36
267
2790
Vascular Surgery
77 [38004496]
7.3e-01
—
—
—
—
1.3e+00
1.2e+00
cases:2.63%
controls:1.29%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.53%
cases:5.73%
controls:1.73%
8
39
296
2995
—
—
—
—
6
16
292
3002
16
49
263
2777
Audiology
64 [38004489]
4.9e-01
—
-1.0e+50
—
—
—
1.2e+00
cases:2.30%
controls:1.42%
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:5.38%
controls:1.63%
7
43
297
2991
—
0
6
305
3038
—
—
—
15
46
264
2780
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
—
—
—
—
8.5e-01
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:2.68%
controls:1.16%
cases:11.11%
controls:3.57%
—
—
—
—
—
8
35
290
2983
31
101
248
2725
pantoprazole; oral, parenteral
A02BC02 [21600097]
5.3e-01
6.6e-01
6.0e-01
—
1.1e+00
5.9e-01
5.4e-01
cases:18.42%
controls:11.73%
cases:11.48%
controls:6.27%
cases:1.97%
controls:1.08%
—
—
cases:2.95%
controls:1.02%
cases:11.07%
controls:6.43%
cases:24.01%
controls:15.50%
56
356
248
2678
35
191
270
2853
6
33
299
3011
—
9
31
296
3011
33
194
265
2824
67
438
212
2388
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.66%
controls:1.45%
—
—
—
—
—
—
13
41
266
2785
aciclovir; oral, parenteral
J05AB01 [21603131]
5.8e-01
4.5e-01
—
—
-1.0e+50
5.0e-01
1.2e+00
cases:4.28%
controls:2.44%
cases:1.64%
controls:1.05%
—
—
—
—
cases:0.00%
controls:0.23%
cases:1.68%
controls:1.03%
cases:8.96%
controls:2.90%
13
74
291
2960
5
32
300
3012
—
—
0
7
305
3035
5
31
293
2987
25
82
254
2744
Person consulting for explanation of investigation findings
Z71.2 [45552100]
4.5e-01
1.1e+00
—
—
—
1.2e+00
7.5e-01
cases:4.28%
controls:2.77%
cases:3.28%
controls:1.12%
—
—
—
—
—
—
cases:4.36%
controls:1.39%
cases:8.60%
controls:4.25%
13
84
291
2950
10
34
295
3010
—
—
—
13
42
285
2976
24
120
255
2706
Other specified special examinations
Z01.8 [45581003]
8.5e-01
1.2e+00
—
—
—
1.3e+00
1.2e+00
cases:4.28%
controls:1.88%
cases:2.62%
controls:0.79%
—
—
—
—
—
—
cases:2.68%
controls:0.73%
cases:7.17%
controls:2.34%
13
57
291
2977
8
24
297
3020
—
—
—
8
22
290
2996
20
66
259
2760
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
6.8e-01
1.2e+00
-1.0e+50
—
—
1.4e-01
6.1e-01
cases:5.92%
controls:3.10%
cases:4.92%
controls:1.58%
cases:0.00%
controls:0.33%
—
—
—
—
cases:2.35%
controls:2.05%
cases:12.19%
controls:7.01%
18
94
286
2940
15
48
290
2996
0
10
305
3034
—
—
7
62
291
2956
34
198
245
2628
Orthopedic Surgery
20 [38004465]
4.5e-01
7.0e-01
—
—
—
1.2e+00
4.2e-01
cases:15.13%
controls:10.18%
cases:8.20%
controls:4.24%
—
—
—
—
—
—
cases:11.41%
controls:3.84%
cases:19.00%
controls:13.38%
46
309
258
2725
25
129
280
2915
—
—
—
34
116
264
2902
53
378
226
2448
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
8.4e-02
2.1e-01
6.7e-01
—
1.2e+00
3.0e-01
2.0e-01
cases:20.07%
controls:18.75%
cases:17.70%
controls:14.85%
cases:5.90%
controls:3.12%
—
—
cases:7.21%
controls:2.37%
cases:20.47%
controls:15.97%
cases:37.63%
controls:33.12%
61
569
243
2465
54
452
251
2592
18
95
287
2949
—
22
72
283
2970
61
482
237
2536
105
936
174
1890
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
-2.5e-01
—
—
—
—
—
1.2e+00
cases:2.63%
controls:3.36%
—
—
—
—
—
—
—
—
—
—
cases:7.89%
controls:2.62%
8
102
296
2932
—
—
—
—
—
22
74
257
2752
Exposure to unspecified factor
X59 [45756412]
7.4e-01
1.6e+00
-1.0e+50
—
—
—
1.2e+00
cases:4.61%
controls:2.24%
cases:1.64%
controls:0.33%
cases:0.00%
controls:0.16%
—
—
—
—
—
—
cases:5.73%
controls:1.88%
14
68
290
2966
5
10
300
3034
0
5
305
3039
—
—
—
16
53
263
2773
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
—
—
—
—
—
6.7e-01
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:1.68%
controls:0.86%
cases:5.38%
controls:1.77%
—
—
—
—
—
5
26
293
2992
15
50
264
2776
General medical examination
Z00.0 [45585791]
3.6e-01
—
—
—
—
—
1.1e+00
cases:2.63%
controls:1.85%
—
—
—
—
—
—
—
—
—
—
cases:5.38%
controls:1.80%
8
56
296
2978
—
—
—
—
—
15
51
264
2775
Ear pain/earache
H01 [2002000475]
6.5e-01
—
—
—
—
-1.0e+50
1.1e+00
cases:2.30%
controls:1.22%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
cases:4.66%
controls:1.59%
7
37
297
2997
—
—
—
—
0
5
298
3013
13
45
266
2781
pH of Serum or Plasma
2753-2 [3018418]
8.4e-01
9.2e-01
—
—
2.1e+00
7.0e-01
1.1e+00
cases:5.59%
controls:2.50%
cases:4.26%
controls:1.74%
—
—
—
—
cases:1.64%
controls:0.20%
cases:3.36%
controls:1.69%
cases:11.83%
controls:4.28%
17
76
287
2958
13
53
292
2991
—
—
5
6
300
3036
10
51
288
2967
33
121
246
2705
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
6.1e-01
1.3e+00
—
—
—
8.0e-01
1.1e+00
cases:2.63%
controls:1.45%
cases:2.95%
controls:0.85%
—
—
—
—
—
—
cases:1.68%
controls:0.76%
cases:5.38%
controls:1.88%
8
44
296
2990
9
26
296
3018
—
—
—
5
23
293
2995
15
53
264
2773
omeprazole; oral, parenteral
A02BC01 [21600096]
1.1e+00
6.8e-01
—
—
—
1.0e+00
7.6e-01
cases:8.88%
controls:3.20%
cases:2.62%
controls:1.35%
—
—
—
—
—
—
cases:3.36%
controls:1.23%
cases:6.81%
controls:3.29%
27
97
277
2937
8
41
297
3003
—
—
—
10
37
288
2981
19
93
260
2733
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
-1.0e+50
—
—
—
—
1.6e+00
1.1e+00
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
cases:2.68%
controls:0.56%
cases:6.45%
controls:2.30%
0
33
304
3001
—
—
—
—
8
17
290
3001
18
65
261
2761
Dizziness and giddiness
R42 [45568132]
5.6e-01
1.6e+00
—
—
—
—
1.1e+00
cases:2.96%
controls:1.71%
cases:2.30%
controls:0.49%
—
—
—
—
—
—
—
—
cases:6.45%
controls:2.30%
9
52
295
2982
7
15
298
3029
—
—
—
—
18
65
261
2761
Pain in joint
M25.5 [45586941]
1.1e+00
6.0e-01
—
—
—
7.2e-01
6.5e-03
cases:6.91%
controls:2.47%
cases:1.97%
controls:1.08%
—
—
—
—
—
—
cases:2.35%
controls:1.16%
cases:5.38%
controls:5.34%
21
75
283
2959
6
33
299
3011
—
—
—
7
35
291
2983
15
151
264
2675
Sleep apnoea
G47.3 [45562094]
-6.4e-02
5.8e-01
—
—
—
8.5e-01
1.1e+00
cases:2.63%
controls:2.80%
cases:2.95%
controls:1.68%
—
—
—
—
—
—
cases:4.70%
controls:2.05%
cases:11.83%
controls:4.42%
8
85
296
2949
9
51
296
2993
—
—
—
14
62
284
2956
33
125
246
2701
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
2.0e-01
1.4e+00
—
—
—
5.3e-01
1.1e+00
cases:5.59%
controls:4.61%
cases:3.28%
controls:0.85%
—
—
—
—
—
—
cases:1.68%
controls:0.99%
cases:7.89%
controls:2.90%
17
140
287
2894
10
26
295
3018
—
—
—
5
30
293
2988
22
82
257
2744
Psychiatry
26 [38004469]
5.9e-01
5.3e-01
2.8e-01
—
—
5.8e-01
1.0e+00
cases:9.54%
controls:5.50%
cases:5.25%
controls:3.15%
cases:1.64%
controls:1.25%
—
—
—
—
cases:5.03%
controls:2.88%
cases:13.98%
controls:5.45%
29
167
275
2867
16
96
289
2948
5
38
300
3006
—
—
15
87
283
2931
39
154
240
2672
Spirometry study
18759-1 [3000492]
7.0e-01
—
—
—
—
—
1.0e+00
cases:2.30%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
cases:5.02%
controls:1.84%
7
35
297
2999
—
—
—
—
—
14
52
265
2774
salmeterol and fluticasone
R03AK06 [21603280]
6.2e-01
8.6e-01
—
—
—
9.1e-01
1.0e+00
cases:4.28%
controls:2.34%
cases:3.28%
controls:1.41%
—
—
—
—
—
—
cases:3.69%
controls:1.52%
cases:6.09%
controls:2.26%
13
71
291
2963
10
43
295
3001
—
—
—
11
46
287
2972
17
64
262
2762
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
1.3e-01
5.4e-01
—
—
—
6.9e-01
1.0e+00
cases:3.29%
controls:2.90%
cases:2.95%
controls:1.74%
—
—
—
—
—
—
cases:2.35%
controls:1.19%
cases:10.04%
controls:3.89%
10
88
294
2946
9
53
296
2991
—
—
—
7
36
291
2982
28
110
251
2716
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
2.9e-01
4.2e-01
5.9e-01
—
7.4e-01
5.6e-01
4.5e-01
cases:41.78%
controls:34.84%
cases:22.62%
controls:16.10%
cases:3.61%
controls:2.04%
—
—
cases:4.59%
controls:2.24%
cases:24.83%
controls:15.94%
cases:49.46%
controls:38.43%
127
1057
177
1977
69
490
236
2554
11
62
294
2982
—
14
68
291
2974
74
481
224
2537
138
1086
141
1740
ibuprofen
R02AX02 [1588667]
2.9e-01
4.2e-01
5.9e-01
—
7.4e-01
5.6e-01
4.5e-01
cases:41.78%
controls:34.84%
cases:22.62%
controls:16.10%
cases:3.61%
controls:2.04%
—
—
cases:4.59%
controls:2.24%
cases:24.83%
controls:15.94%
cases:49.46%
controls:38.43%
127
1057
177
1977
69
490
236
2554
11
62
294
2982
—
14
68
291
2974
74
481
224
2537
138
1086
141
1740
lansoprazole; oral
A02BC03 [21600098]
1.0e+00
9.4e-01
-1.0e+50
—
—
7.2e-01
7.5e-01
cases:8.88%
controls:3.46%
cases:4.26%
controls:1.71%
cases:0.00%
controls:0.30%
—
—
—
—
cases:3.36%
controls:1.66%
cases:7.17%
controls:3.50%
27
105
277
2929
13
52
292
2992
0
9
305
3035
—
—
10
50
288
2968
20
99
259
2727
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
6.0e-03
1.0e+00
—
—
1.5e+00
5.7e-01
4.7e-01
cases:4.28%
controls:4.25%
cases:5.25%
controls:2.00%
—
—
—
—
cases:1.97%
controls:0.46%
cases:4.36%
controls:2.52%
cases:11.11%
controls:7.25%
13
129
291
2905
16
61
289
2983
—
—
6
14
299
3028
13
76
285
2942
31
205
248
2621
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.3e-01
1.3e-01
2.5e-01
—
9.9e-01
5.0e-01
4.2e-01
cases:14.80%
controls:12.10%
cases:12.13%
controls:10.84%
cases:3.61%
controls:2.83%
—
—
cases:5.90%
controls:2.27%
cases:17.11%
controls:11.17%
cases:34.41%
controls:25.69%
45
367
259
2667
37
330
268
2714
11
86
294
2958
—
18
69
287
2973
51
337
247
2681
96
726
183
2100
fluconazole; oral, parenteral
J02AC01 [21603080]
6.1e-01
9.8e-01
-1.0e+50
—
—
7.4e-01
6.8e-01
cases:11.18%
controls:6.43%
cases:5.25%
controls:2.04%
cases:0.00%
controls:0.39%
—
—
—
—
cases:4.03%
controls:1.95%
cases:9.32%
controls:4.95%
34
195
270
2839
16
62
289
2982
0
12
305
3032
—
—
12
59
286
2959
26
140
253
2686
CBC panel - Blood by Automated count
58410-2 [40761511]
1.8e-01
3.2e-01
6.8e-01
—
9.7e-01
4.3e-01
2.0e-01
cases:23.03%
controls:19.94%
cases:18.36%
controls:14.09%
cases:5.25%
controls:2.73%
—
—
cases:6.23%
controls:2.47%
cases:21.14%
controls:14.81%
cases:38.71%
controls:34.15%
70
605
234
2429
56
429
249
2615
16
83
289
2961
—
19
75
286
2967
63
447
235
2571
108
965
171
1861
enoxaparin; parenteral
B01AB05 [21600976]
5.8e-01
—
—
—
-1.0e+50
4.3e-01
9.4e-01
cases:4.61%
controls:2.64%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:1.68%
controls:1.09%
cases:8.24%
controls:3.40%
14
80
290
2954
—
—
—
0
6
305
3036
5
33
293
2985
23
96
256
2730
furosemide; oral, parenteral
C03CA01 [21601518]
2.7e-01
2.9e-01
—
—
—
4.1e-01
9.4e-01
cases:2.96%
controls:2.27%
cases:2.95%
controls:2.23%
—
—
—
—
—
—
cases:3.02%
controls:2.02%
cases:8.96%
controls:3.72%
9
69
295
2965
9
68
296
2976
—
—
—
9
61
289
2957
25
105
254
2721
Bacteria identified in Blood by Culture
600-7 [3023368]
6.6e-01
—
—
—
—
—
9.4e-01
cases:3.95%
controls:2.08%
—
—
—
—
—
—
—
—
—
—
cases:8.96%
controls:3.72%
12
63
292
2971
—
—
—
—
—
25
105
254
2721
zolpidem; oral
N05CF02 [21604655]
7.2e-01
6.8e-01
—
—
—
8.2e-01
9.3e-01
cases:5.26%
controls:2.64%
cases:2.95%
controls:1.51%
—
—
—
—
—
—
cases:3.69%
controls:1.66%
cases:6.81%
controls:2.80%
16
80
288
2954
9
46
296
2998
—
—
—
11
50
287
2968
19
79
260
2747
Urgent procedure
ZXD05 [2001311386]
-1.8e-01
—
—
—
-1.0e+50
—
9.2e-01
cases:3.29%
controls:3.92%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
cases:6.81%
controls:2.83%
10
119
294
2915
—
—
—
0
5
305
3037
—
19
80
260
2746
Bacteria identified in Urine by Culture
630-4 [3026008]
3.9e-01
—
—
—
—
1.7e-01
9.2e-01
cases:3.62%
controls:2.47%
—
—
—
—
—
—
—
—
cases:1.68%
controls:1.42%
cases:10.39%
controls:4.42%
11
75
293
2959
—
—
—
—
5
43
293
2975
29
125
250
2701
fusidic acid
D09AA02 [21602265]
2.2e-01
—
—
—
—
—
9.1e-01
cases:3.29%
controls:2.67%
—
—
—
—
—
—
—
—
—
—
cases:7.17%
controls:3.01%
10
81
294
2953
—
—
—
—
—
20
85
259
2741
fusidic acid; ointment
D06AX01 [21602062]
2.2e-01
—
—
—
—
—
9.1e-01
cases:3.29%
controls:2.67%
—
—
—
—
—
—
—
—
—
—
cases:7.17%
controls:3.01%
10
81
294
2953
—
—
—
—
—
20
85
259
2741
Short blood count panel - Blood
55429-5 [40758558]
5.3e-01
7.4e-02
—
—
—
—
9.1e-01
cases:6.25%
controls:3.79%
cases:2.30%
controls:2.14%
—
—
—
—
—
—
—
—
cases:11.11%
controls:4.81%
19
115
285
2919
7
65
298
2979
—
—
—
—
31
136
248
2690
General Practice
1 [38004446]
4.5e-01
5.5e-01
—
—
1.8e+00
6.8e-01
9.0e-01
cases:12.83%
controls:8.57%
cases:4.92%
controls:2.89%
—
—
—
—
cases:1.64%
controls:0.26%
cases:5.70%
controls:2.98%
cases:20.43%
controls:9.41%
39
260
265
2774
15
88
290
2956
—
—
5
8
300
3034
17
90
281
2928
57
266
222
2560
Other specified counselling
Z71.8 [45581061]
3.1e-01
7.8e-01
—
—
—
9.0e-01
8.8e-01
cases:4.28%
controls:3.16%
cases:2.95%
controls:1.38%
—
—
—
—
—
—
cases:4.36%
controls:1.82%
cases:13.62%
controls:6.12%
13
96
291
2938
9
42
296
3002
—
—
—
13
55
285
2963
38
173
241
2653
Tissue Pathology biopsy report
66121-5 [40768804]
-4.4e-01
3.3e-01
—
—
—
1.8e-01
8.5e-01
cases:3.29%
controls:5.01%
cases:2.95%
controls:2.14%
—
—
—
—
—
—
cases:2.68%
controls:2.25%
cases:12.90%
controls:5.94%
10
152
294
2882
9
65
296
2979
—
—
—
8
68
290
2950
36
168
243
2658
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
1.9e-01
1.2e-01
—
—
—
4.7e-01
8.3e-01
cases:4.28%
controls:3.56%
cases:1.97%
controls:1.74%
—
—
—
—
—
—
cases:2.68%
controls:1.69%
cases:9.68%
controls:4.46%
13
108
291
2926
6
53
299
2991
—
—
—
8
51
290
2967
27
126
252
2700
Acute maxillary sinusitis
J01.0 [45601112]
3.7e-01
7.8e-01
—
—
-1.0e+50
1.1e+00
8.3e-01
cases:3.95%
controls:2.77%
cases:1.64%
controls:0.76%
—
—
—
—
cases:0.00%
controls:0.20%
cases:2.01%
controls:0.70%
cases:10.04%
controls:4.64%
12
84
292
2950
5
23
300
3021
—
—
0
6
305
3036
6
21
292
2997
28
131
251
2695
General Surgery
2 [38004447]
4.1e-01
7.5e-01
—
—
—
8.2e-01
4.2e-01
cases:22.37%
controls:16.05%
cases:8.20%
controls:4.04%
—
—
—
—
—
—
cases:9.06%
controls:4.21%
cases:17.92%
controls:12.53%
68
487
236
2547
25
123
280
2921
—
—
—
27
127
271
2891
50
354
229
2472
Other and unspecified abdominal pain
R10.4 [45568113]
6.5e-01
1.5e-01
—
—
—
5.0e-01
8.1e-01
cases:7.57%
controls:4.09%
cases:1.64%
controls:1.41%
—
—
—
—
—
—
cases:2.01%
controls:1.23%
cases:9.68%
controls:4.56%
23
124
281
2910
5
43
300
3001
—
—
—
6
37
292
2981
27
129
252
2697
Treatment plan or consultation
WZC00 [2001310885]
6.0e-03
-1.2e-01
—
—
—
—
8.0e-01
cases:4.28%
controls:4.25%
cases:1.64%
controls:1.84%
—
—
—
—
—
—
—
—
cases:8.96%
controls:4.25%
13
129
291
2905
5
56
300
2988
—
—
—
—
25
120
254
2706
calcium (different salts in combination); oral
A12AA20 [21600872]
4.9e-01
2.8e-01
7.4e-01
—
8.7e-01
6.3e-01
8.0e-01
cases:7.89%
controls:4.98%
cases:4.92%
controls:3.75%
cases:1.64%
controls:0.79%
—
—
cases:1.64%
controls:0.69%
cases:6.38%
controls:3.51%
cases:13.98%
controls:6.83%
24
151
280
2883
15
114
290
2930
5
24
300
3020
—
5
21
300
3021
19
106
279
2912
39
193
240
2633
Upper gastrointestinal surgery
106 [44777669]
5.2e-01
7.6e-01
—
—
—
3.4e-01
7.8e-01
cases:9.87%
controls:6.13%
cases:5.25%
controls:2.53%
—
—
—
—
—
—
cases:3.36%
controls:2.42%
cases:14.70%
controls:7.29%
30
186
274
2848
16
77
289
2967
—
—
—
10
73
288
2945
41
206
238
2620
Extended examination of mouth
SAA03 [2001310276]
2.2e-01
1.4e-01
-1.0e+50
—
—
3.6e-01
7.8e-01
cases:8.55%
controls:6.95%
cases:2.30%
controls:2.00%
cases:0.00%
controls:0.16%
—
—
—
—
cases:2.35%
controls:1.66%
cases:13.26%
controls:6.55%
26
211
278
2823
7
61
298
2983
0
5
305
3039
—
—
7
50
291
2968
37
185
242
2641
hydrocortisone
C05AA01 [21601608]
7.6e-01
4.0e-01
—
—
—
8.5e-01
4.1e-01
cases:13.16%
controls:6.62%
cases:2.95%
controls:2.00%
—
—
—
—
—
—
cases:5.03%
controls:2.22%
cases:9.68%
controls:6.62%
40
201
264
2833
9
61
296
2983
—
—
—
15
67
283
2951
27
187
252
2639
hydrocortisone
A07EA02 [21600654]
7.6e-01
4.0e-01
—
—
—
8.5e-01
4.1e-01
cases:13.16%
controls:6.62%
cases:2.95%
controls:2.00%
—
—
—
—
—
—
cases:5.03%
controls:2.22%
cases:9.68%
controls:6.62%
40
201
264
2833
9
61
296
2983
—
—
—
15
67
283
2951
27
187
252
2639
Home Visit
OMOP4822459 [581476]
4.2e-01
7.0e-01
—
-1.0e+50
—
8.9e-01
7.6e-01
cases:3.95%
controls:2.64%
cases:2.30%
controls:1.15%
—
—
cases:0.00%
controls:0.16%
—
—
cases:5.03%
controls:2.12%
cases:10.39%
controls:5.17%
12
80
292
2954
7
35
298
3009
—
0
5
305
3039
—
15
64
283
2954
29
146
250
2680
cefalexin; oral
J01DB01 [21602870]
3.4e-01
5.0e-01
6.2e-01
—
—
3.8e-01
7.6e-01
cases:33.88%
controls:26.76%
cases:12.13%
controls:7.75%
cases:1.64%
controls:0.89%
—
—
—
—
cases:13.09%
controls:9.31%
cases:41.94%
controls:25.34%
103
812
201
2222
37
236
268
2808
5
27
300
3017
—
—
39
281
259
2737
117
716
162
2110
betamethasone
D07AC01 [21602120]
6.2e-01
8.2e-01
—
—
—
5.4e-01
7.5e-01
cases:9.87%
controls:5.57%
cases:3.93%
controls:1.77%
—
—
—
—
—
—
cases:3.36%
controls:1.99%
cases:12.54%
controls:6.37%
30
169
274
2865
12
54
293
2990
—
—
—
10
60
288
2958
35
180
244
2646
betamethasone
C05AA05 [21601610]
6.2e-01
8.2e-01
—
—
—
5.4e-01
7.5e-01
cases:9.87%
controls:5.57%
cases:3.93%
controls:1.77%
—
—
—
—
—
—
cases:3.36%
controls:1.99%
cases:12.54%
controls:6.37%
30
169
274
2865
12
54
293
2990
—
—
—
10
60
288
2958
35
180
244
2646
betamethasone
S02BA07 [21605169]
6.2e-01
8.2e-01
—
—
—
5.4e-01
7.5e-01
cases:9.87%
controls:5.57%
cases:3.93%
controls:1.77%
—
—
—
—
—
—
cases:3.36%
controls:1.99%
cases:12.54%
controls:6.37%
30
169
274
2865
12
54
293
2990
—
—
—
10
60
288
2958
35
180
244
2646
betamethasone
A07EA04 [21600656]
6.2e-01
8.2e-01
—
—
—
5.4e-01
7.5e-01
cases:9.87%
controls:5.57%
cases:3.93%
controls:1.77%
—
—
—
—
—
—
cases:3.36%
controls:1.99%
cases:12.54%
controls:6.37%
30
169
274
2865
12
54
293
2990
—
—
—
10
60
288
2958
35
180
244
2646
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
1.7e-01
6.0e-01
—
—
1.5e+00
7.5e-01
4.1e-01
cases:11.18%
controls:9.62%
cases:9.84%
controls:5.65%
—
—
—
—
cases:2.62%
controls:0.59%
cases:10.74%
controls:5.40%
cases:24.73%
controls:17.91%
34
292
270
2742
30
172
275
2872
—
—
8
18
297
3024
32
163
266
2855
69
506
210
2320
hydrocortisone butyrate
D07AB02 [21602106]
7.4e-01
3.1e-01
-1.0e+50
—
—
7.8e-01
4.1e-01
cases:12.83%
controls:6.56%
cases:2.62%
controls:1.94%
cases:0.00%
controls:0.26%
—
—
—
—
cases:4.70%
controls:2.22%
cases:9.68%
controls:6.62%
39
199
265
2835
8
59
297
2985
0
8
305
3036
—
—
14
67
284
2951
27
187
252
2639
hydrocortisone
D07AA02 [21602102]
7.4e-01
3.1e-01
-1.0e+50
—
—
7.8e-01
4.1e-01
cases:12.83%
controls:6.56%
cases:2.62%
controls:1.94%
cases:0.00%
controls:0.26%
—
—
—
—
cases:4.70%
controls:2.22%
cases:9.68%
controls:6.62%
39
199
265
2835
8
59
297
2985
0
8
305
3036
—
—
14
67
284
2951
27
187
252
2639
hydrocortisone aceponate
D07AC16 [21602135]
7.4e-01
3.1e-01
-1.0e+50
—
—
7.8e-01
4.1e-01
cases:12.83%
controls:6.56%
cases:2.62%
controls:1.94%
cases:0.00%
controls:0.26%
—
—
—
—
cases:4.70%
controls:2.22%
cases:9.68%
controls:6.62%
39
199
265
2835
8
59
297
2985
0
8
305
3036
—
—
14
67
284
2951
27
187
252
2639
hydrocortisone buteprate
D07AB11 [21602115]
7.4e-01
3.1e-01
-1.0e+50
—
—
7.8e-01
4.1e-01
cases:12.83%
controls:6.56%
cases:2.62%
controls:1.94%
cases:0.00%
controls:0.26%
—
—
—
—
cases:4.70%
controls:2.22%
cases:9.68%
controls:6.62%
39
199
265
2835
8
59
297
2985
0
8
305
3036
—
—
14
67
284
2951
27
187
252
2639
etoricoxib; oral
M01AH05 [21603996]
5.4e-01
2.9e-01
—
—
—
7.4e-01
2.6e-01
cases:16.45%
controls:10.28%
cases:5.90%
controls:4.50%
—
—
—
—
—
—
cases:9.73%
controls:4.90%
cases:20.07%
controls:16.17%
50
312
254
2722
18
137
287
2907
—
—
—
29
148
269
2870
56
457
223
2369
Normoblasts [#/volume] in Blood
715-3 [3021589]
4.7e-01
3.4e-01
4.9e-01
—
1.3e+00
5.3e-01
7.3e-01
cases:7.89%
controls:5.08%
cases:5.90%
controls:4.27%
cases:2.30%
controls:1.41%
—
—
cases:2.30%
controls:0.62%
cases:7.05%
controls:4.27%
cases:17.92%
controls:9.48%
24
154
280
2880
18
130
287
2914
7
43
298
3001
—
7
19
298
3023
21
129
277
2889
50
268
229
2558
antibiotics in combination with other drugs
S01AA20 [21603571]
6.3e-01
7.5e-01
—
—
—
8.8e-01
7.3e-01
cases:9.54%
controls:5.31%
cases:3.28%
controls:1.58%
—
—
—
—
—
—
cases:3.36%
controls:1.42%
cases:11.47%
controls:5.87%
29
161
275
2873
10
48
295
2996
—
—
—
10
43
288
2975
32
166
247
2660
combinations of corticosteroids
D07AB30 [21602118]
7.1e-01
5.6e-01
—
—
—
3.6e-01
4.9e-01
cases:15.79%
controls:8.47%
cases:4.92%
controls:2.86%
—
—
—
—
—
—
cases:4.03%
controls:2.85%
cases:15.77%
controls:10.30%
48
257
256
2777
15
87
290
2957
—
—
—
12
86
286
2932
44
291
235
2535
combinations of corticosteroids
D07XB30 [21602188]
7.1e-01
5.6e-01
—
—
—
3.6e-01
4.9e-01
cases:15.79%
controls:8.47%
cases:4.92%
controls:2.86%
—
—
—
—
—
—
cases:4.03%
controls:2.85%
cases:15.77%
controls:10.30%
48
257
256
2777
15
87
290
2957
—
—
—
12
86
286
2932
44
291
235
2535
hydrocortisone
S02BA01 [21605166]
7.0e-01
3.9e-02
-1.0e+50
—
—
8.1e-01
3.1e-01
cases:10.86%
controls:5.70%
cases:1.64%
controls:1.58%
cases:0.00%
controls:0.23%
—
—
—
—
cases:4.36%
controls:1.99%
cases:7.89%
controls:5.91%
33
173
271
2861
5
48
300
2996
0
7
305
3037
—
—
13
60
285
2958
22
167
257
2659
prednisolone; oral, parenteral
H02AB06 [21602734]
4.9e-01
1.4e-01
—
—
—
5.8e-01
6.8e-01
cases:12.50%
controls:8.08%
cases:3.93%
controls:3.45%
—
—
—
—
—
—
cases:5.70%
controls:3.28%
cases:16.85%
controls:9.31%
38
245
266
2789
12
105
293
2939
—
—
—
17
99
281
2919
47
263
232
2563
prednisolone
A07EA01 [21600653]
4.9e-01
1.4e-01
—
—
—
5.8e-01
6.8e-01
cases:12.50%
controls:8.08%
cases:3.93%
controls:3.45%
—
—
—
—
—
—
cases:5.70%
controls:3.28%
cases:16.85%
controls:9.34%
38
245
266
2789
12
105
293
2939
—
—
—
17
99
281
2919
47
264
232
2562
pivmecillinam; oral
J01CA08 [21602827]
1.7e-01
6.5e-01
—
—
—
5.2e-01
6.6e-01
cases:8.22%
controls:7.05%
cases:3.93%
controls:2.10%
—
—
—
—
—
—
cases:3.69%
controls:2.22%
cases:13.62%
controls:7.50%
25
214
279
2820
12
64
293
2980
—
—
—
11
67
287
2951
38
212
241
2614
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.7e-01
4.2e-01
8.6e-01
—
1.0e+00
7.7e-01
6.5e-01
cases:6.91%
controls:5.90%
cases:5.57%
controls:3.75%
cases:2.30%
controls:0.99%
—
—
cases:1.97%
controls:0.72%
cases:6.71%
controls:3.21%
cases:16.85%
controls:9.55%
21
179
283
2855
17
114
288
2930
7
30
298
3014
—
6
22
299
3020
20
97
278
2921
47
270
232
2556
esomeprazole; oral, parenteral
A02BC05 [21600100]
6.4e-01
5.1e-01
—
—
—
6.3e-01
3.8e-01
cases:12.17%
controls:6.79%
cases:5.90%
controls:3.61%
—
—
—
—
—
—
cases:6.38%
controls:3.51%
cases:11.83%
controls:8.39%
37
206
267
2828
18
110
287
2934
—
—
—
19
106
279
2912
33
237
246
2589
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
-6.2e-03
-2.4e-02
8.8e-01
—
9.7e-01
4.3e-01
6.3e-01
cases:8.88%
controls:8.93%
cases:4.59%
controls:4.70%
cases:1.97%
controls:0.82%
—
—
cases:1.97%
controls:0.76%
cases:7.05%
controls:4.71%
cases:23.66%
controls:14.19%
27
271
277
2763
14
143
291
2901
6
25
299
3019
—
6
23
299
3019
21
142
277
2876
66
401
213
2425
mometasone; nasal
R01AD09 [21605051]
2.7e-01
4.0e-01
—
—
—
5.6e-01
6.0e-01
cases:12.17%
controls:9.56%
cases:4.59%
controls:3.12%
—
—
—
—
—
—
cases:5.37%
controls:3.15%
cases:15.77%
controls:9.34%
37
290
267
2744
14
95
291
2949
—
—
—
16
95
282
2923
44
264
235
2562
pseudoephedrine, combinations; oral
R01BA52 [21603213]
3.2e-01
-1.3e-01
—
—
-1.0e+50
1.2e-01
5.9e-01
cases:13.16%
controls:9.89%
cases:2.62%
controls:2.99%
—
—
—
—
cases:0.00%
controls:0.36%
cases:3.69%
controls:3.28%
cases:17.56%
controls:10.54%
40
300
264
2734
8
91
297
2953
—
—
0
11
305
3031
11
99
287
2919
49
298
230
2528
Infiltration anesthesia
WX110 [2001310767]
2.7e-01
4.1e-01
9.2e-01
—
—
4.0e-01
4.9e-01
cases:17.76%
controls:14.14%
cases:9.18%
controls:6.27%
cases:1.64%
controls:0.66%
—
—
—
—
cases:9.40%
controls:6.53%
cases:27.96%
controls:19.14%
54
429
250
2605
28
191
277
2853
5
20
300
3024
—
—
28
197
270
2821
78
541
201
2285
Rupture of aminiotic membrane for induction of labor
MAC01 [2001306869]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
304
3025
—
—
—
—
—
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
3.6e-01
2.5e-01
—
—
—
2.2e-01
2.7e-01
cases:3.29%
controls:2.31%
cases:1.97%
controls:1.54%
—
—
—
—
—
—
cases:2.01%
controls:1.62%
cases:7.53%
controls:5.84%
10
70
294
2964
6
47
299
2997
—
—
—
6
49
292
2969
21
165
258
2661
Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid
22118-4 [3011166]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
5
279
2821
Congestive heart failure
I50.0 [45567179]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
5
304
3029
—
—
—
—
0
9
298
3009
—
azathioprine; oral, parenteral
L04AX01 [21603927]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.20%
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.46%
—
0
18
305
3026
0
6
305
3038
—
0
5
305
3037
0
15
298
3003
0
13
279
2813
EKG study
11524-6 [3013512]
7.6e-01
3.6e-01
—
—
—
7.4e-01
3.8e-01
cases:5.59%
controls:2.70%
cases:2.30%
controls:1.61%
—
—
—
—
—
—
cases:3.69%
controls:1.79%
cases:8.24%
controls:5.80%
17
82
287
2952
7
49
298
2995
—
—
—
11
54
287
2964
23
164
256
2662
Urinary tract ultrasound examination
KH1AE [2001306329]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
304
3024
—
—
—
—
—
—
Other specified diseases of hard tissues of teeth
K03.88 [2000502701]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
0
5
304
3029
—
—
—
—
—
0
5
279
2821
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.68%
controls:0.33%
—
—
—
—
—
—
—
5
10
293
3008
—
nepafenac
S01BC10 [21603648]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
0
5
305
3039
—
—
—
—
—
metronidazole and furazolidone
P01AB51 [45893518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
304
3025
—
—
—
—
—
—
Neonatal screening
60151004 [4246502]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
0
6
279
2820
benzoyl peroxide, combinations
D10AE51 [21602303]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
304
3027
—
—
—
—
—
—
Unstable angina
I20.00 [2000502384]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
304
3028
—
—
—
—
—
—
Other specified pulpit
K04.08 [2000502703]
—
-1.0e+50
—
—
—
—
8.2e-01
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.45%
—
0
10
305
3034
—
—
—
—
9
41
270
2785
calcium carbonate
A02AC01 [21600065]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.20%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
0
6
304
3028
0
7
305
3037
—
—
—
0
7
298
3011
—
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
1.3e+00
—
—
—
—
—
7.0e-01
cases:3.29%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.63%
10
28
294
3006
—
—
—
—
—
9
46
270
2780
Special examination of mouth
SAA04 [2001310277]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
0
5
305
3039
—
—
—
—
—
Other internal derangements of knee
M23.8 [45548371]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
0
6
279
2820
Other obesity
E66.8 [45533036]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
0
7
305
3037
—
—
—
—
0
17
279
2809
Maternal care due to uterine scar from previous surgery
O34.2 [45572805]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
0
10
305
3034
—
—
—
—
0
21
279
2805
cetirizine; oral
R06AE07 [21603497]
4.0e-01
4.6e-01
—
—
9.7e-01
3.8e-01
5.3e-01
cases:12.17%
controls:8.54%
cases:5.25%
controls:3.38%
—
—
—
—
cases:1.64%
controls:0.62%
cases:5.37%
controls:3.74%
cases:12.19%
controls:7.54%
37
259
267
2775
16
103
289
2941
—
—
5
19
300
3023
16
113
282
2905
34
213
245
2613
misoprostol; oral
A02BB01 [21600093]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
0
6
298
3012
—
Primary coxarthrosis, bilateral
M16.0 [45543482]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
cases:0.00%
controls:0.85%
—
—
—
—
—
0
5
298
3013
0
24
279
2802
folic acid
V04CX02 [715877]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
0
15
298
3003
—
Carboxyhemoglobin/Hemoglobin.total in Venous blood
2032-1 [3010517]
-1.0e+50
—
—
—
—
—
8.9e-01
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.74%
0
9
304
3025
—
—
—
—
—
5
21
274
2805
terfenadine; oral
R06AX12 [21603513]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
304
3027
—
—
—
—
—
—
Delivery in a completely normal case[PARTUS SINE COMPLICATIONE]
6500B [2000405100]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
304
3027
—
—
—
—
—
—
insulin (beef); parenteral
A10AD02 [21600730]
—
—
-1.0e+50
—
—
—
8.4e-02
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:3.23%
controls:2.97%
—
—
0
24
305
3020
—
—
—
9
84
270
2742
Hand Surgery
40 [38004480]
4.0e-01
—
—
—
—
7.5e-01
2.1e-01
cases:2.96%
controls:2.01%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.96%
cases:3.94%
controls:3.22%
9
61
295
2973
—
—
—
—
6
29
292
2989
11
91
268
2735
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
—
—
-1.0e+50
—
-1.0e+50
—
-8.4e-02
—
—
—
—
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.20%
—
—
cases:2.15%
controls:2.34%
—
—
0
7
305
3037
—
0
6
305
3036
—
6
66
273
2760
Trisomy 18 risk [Likelihood] in Fetus
43994-3 [3047352]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
0
14
304
3020
0
15
305
3029
—
—
—
0
8
298
3010
—
paroxetine; oral
N06AB05 [21604713]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
0
5
305
3039
—
—
—
—
Diabetes insulin dependent
T89 [2002001130]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:1.42%
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.16%
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.89%
—
—
0
43
304
2991
0
28
305
3016
0
5
305
3039
—
0
11
305
3031
0
27
298
2991
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
4.3e-02
2.5e-01
-1.0e+50
—
—
7.2e-01
3.1e-01
cases:2.30%
controls:2.21%
cases:1.64%
controls:1.28%
cases:0.00%
controls:0.16%
—
—
—
—
cases:2.35%
controls:1.16%
cases:4.66%
controls:3.47%
7
67
297
2967
5
39
300
3005
0
5
305
3039
—
—
7
35
291
2983
13
98
266
2728
ERCP
UJK02 [2001305365]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
5
279
2821
Missed abortion
O02.1 [45567878]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
23
279
2803
prochlorperazine; oral, parenteral, rectal
N05AB04 [21604503]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
11
279
2815
s-atenolol; oral
C07AB11 [21601693]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
0
6
305
3036
—
—
methylprednisolone, combinations
H02BX01 [21602747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
0
6
279
2820
Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium
O99.89 [2000503220]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
304
3029
—
—
—
—
—
—
ketoprofen, combinations
M01AE53 [21603985]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
304
3027
—
—
—
—
—
—
isradipine; oral, parenteral
C08CA03 [21601749]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
304
3029
—
—
—
—
—
—
Treatment-related counselling outside office
SPAT1249 [2001700350]
1.6e-01
7.7e-01
—
—
—
5.2e-02
5.0e-01
cases:6.25%
controls:5.37%
cases:5.25%
controls:2.50%
—
—
—
—
—
—
cases:2.68%
controls:2.55%
cases:12.19%
controls:7.78%
19
163
285
2871
16
76
289
2968
—
—
—
8
77
290
2941
34
220
245
2606
sertraline; oral
N06AB06 [21604714]
4.9e-01
8.7e-01
-1.0e+50
—
—
9.8e-01
1.4e-01
cases:2.30%
controls:1.42%
cases:1.64%
controls:0.69%
cases:0.00%
controls:0.16%
—
—
—
—
cases:2.01%
controls:0.76%
cases:1.79%
controls:1.56%
7
43
297
2991
5
21
300
3023
0
5
305
3039
—
—
6
23
292
2995
5
44
274
2782
Compression of nerve roots and nerve plexus in disc diseases in the lumbar region and other regions
G55.1*M51.1 [2000502168]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
0
8
279
2818
Essential (primary) hypertension
I10 [45591453]
9.7e-02
6.7e-01
—
1.0e+50
—
3.9e-01
5.7e-02
cases:9.54%
controls:8.73%
cases:7.87%
controls:4.20%
—
—
cases:1.64%
controls:0.00%
—
—
cases:6.71%
controls:4.64%
cases:15.41%
controls:14.69%
29
265
275
2769
24
128
281
2916
—
5
0
300
3044
—
20
140
278
2878
43
415
236
2411
Excessive bleeding in the premenopausal period
N92.4 [45606518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
304
3026
—
—
—
—
—
—
pegfilgrastim; parenteral
L03AA13 [21603856]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
0
10
304
3024
0
6
305
3038
—
—
—
—
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
5.9e-01
5.5e-01
—
—
—
9.4e-01
8.3e-01
cases:3.29%
controls:1.85%
cases:1.97%
controls:1.15%
—
—
—
—
—
—
cases:1.68%
controls:0.66%
cases:4.66%
controls:2.09%
10
56
294
2978
6
35
299
3009
—
—
—
5
20
293
2998
13
59
266
2767
Structured assessment of psychoactive substance / tobacco use
SPAT1273 [2001700374]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
304
3022
—
—
—
—
—
—
Pap smear
SPAT1193 [2001700294]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
8
298
3010
—
ranitidine bismuth citrate; oral
A02BA07 [21600088]
4.3e-01
—
—
—
—
—
5.7e-01
cases:2.96%
controls:1.94%
—
—
—
—
—
—
—
—
—
—
cases:1.79%
controls:1.03%
9
59
295
2975
—
—
—
—
—
5
29
274
2797
metoprolol and felodipine
C07FB02 [21601742]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.39%
0
13
304
3021
0
10
305
3034
—
—
—
0
9
298
3009
0
11
279
2815
methylphenidate; oral
N06BA04 [21604757]
—
—
-1.0e+50
—
—
—
8.9e-01
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:1.79%
controls:0.74%
—
—
0
6
305
3038
—
—
—
5
21
274
2805

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
184
788
4.30
35.46
3.4
2.1
295.39
172.87
u/l
1.68
176
752
133
666
2.75
16.44
3.0
3.3
850.32
934.62
ng/l
0.10
112
558
197
1254
2.58
14.18
7.8
7.1
1.21
1.21
mmol/l
0.26
178
1085
68
264
3.02
13.20
9.3
8.6
5.31
5.15
kpa
0.56
68
256
68
264
3.02
13.20
9.3
8.6
12.01
12.74
kpa
0.54
68
257
67
263
2.98
12.72
9.4
8.7
7.42
7.42
ph
0.00
38
153
65
254
2.97
12.42
9.4
8.9
1.69
0.99
mmol/l
0.68
58
216
88
413
2.58
11.78
1.4
1.4
1061.54
573.49
titre
0.58
13
86
171
1134
2.14
9.70
7.6
6.4
1.21
1.21
mmol/l
0.21
165
1053
169
1125
2.11
9.39
5.1
4.8
35.67
36.60
g/l
1.25
157
1074
187
1294
2.13
9.36
5.7
6.9
8.96
8.77
%
0.36
180
1236
190
1337
2.09
8.92
5.7
6.8
28.87
28.98
%
0.05
183
1286
42
154
3.00
8.87
1.9
3.6
129.51
118.16
ng/l
0.10
35
141
255
2034
2.45
8.45
8.2
8.1
82.41
77.88
u/l
0.73
249
1938
138
885
2.01
8.15
4.6
6.7
—
—
—
0
0
182
1287
2.01
8.12
5.8
6.8
3.07
2.85
%
0.61
176
1226
208
1543
2.06
8.10
6.5
4.8
6.37
6.50
mmol/l
0.47
198
1452
182
1289
2.00
8.06
5.8
6.8
0.70
0.71
%
0.11
175
1220
60
279
2.43
7.95
1.6
2.0
362.26
366.36
nmol/l
0.06
53
264
199
1460
2.02
7.90
6.6
6.9
0.20
0.19
e9/l
0.56
175
1292
160
1090
1.97
7.86
1.9
2.0
96.08
96.22
pmol/l
0.01
87
556
76
397
2.21
7.68
2.7
2.8
2.89
2.22
e6/l
0.26
33
184
193
1409
1.98
7.67
5.9
6.7
0.56
0.56
e9/l
0.03
165
1225
193
1412
1.98
7.59
5.9
6.7
0.04
0.04
e9/l
0.02
163
1226
121
759
1.98
7.46
4.1
4.1
7.40
7.40
ph
0.25
92
539
195
1450
1.93
7.10
5.8
6.7
1.89
2.02
e9/l
0.62
172
1294
65
329
2.24
7.05
8.6
6.9
105.52
104.35
mmol/l
1.36
65
329
34
126
2.91
7.03
7.1
4.6
—
—
—
0
0
180
1313
1.89
6.85
5.9
6.7
54.69
56.56
%
1.20
175
1270
168
1206
1.86
6.65
2.7
2.5
77.63
75.71
nmol/l
0.36
158
1099
36
142
2.74
6.64
14.8
9.3
16.36
16.28
%
0.05
36
137
85
489
2.02
6.58
3.9
3.7
186.61
281.23
ng/l
0.35
64
341
203
1566
1.86
6.19
7.4
10.4
3.95
3.91
e9/l
0.07
175
1378
108
693
1.86
5.96
2.6
2.8
—
—
—
0
0
122
825
1.79
5.61
3.4
3.0
16.97
129.40
e6/l
0.80
85
629
107
698
1.82
5.53
1.6
1.6
19.66
20.88
nmol/l
0.47
97
594
44
210
2.28
5.44
12.1
9.6
—
—
—
0
0
58
310
2.07
5.41
1.7
1.7
—
—
—
0
0
47
235
2.18
5.19
5.3
4.7
0.00
0.16
%
—
8
57
33
142
2.48
5.13
1.7
2.6
—
—
—
0
0
10
12
8.57
5.10
3.3
4.2
29.30
33.23
umol/l
—
10
6
47
237
2.16
5.09
6.0
5.1
0.00
0.12
%
—
8
49
107
713
1.77
5.08
3.2
2.9
0.37
0.41
e6/l
0.11
70
510
98
641
1.77
4.94
2.4
2.1
2.99
2.90
mg/l
0.10
87
562
47
240
2.13
4.92
5.2
4.6
0.30
0.67
%
—
10
66
99
652
1.76
4.86
3.9
4.4
—
—
—
0
0
185
1451
1.69
4.71
6.7
6.4
11.06
11.06
umol/l
0.00
178
1383
155
1161
1.67
4.71
13.3
10.3
1.16
1.16
inr
0.02
132
953
16
48
3.46
4.67
2.6
2.6
—
—
—
0
0
173
1338
1.67
4.61
3.4
3.1
114.42
118.51
ug/l
0.10
167
1263
17
54
3.27
4.56
1.2
1.1
2.41
1.71
u/ml
—
10
32
66
392
1.87
4.52
1.5
1.6
—
—
—
0
0
161
1228
1.65
4.49
11.9
11.1
0.00
0.00
e9/l
0.26
128
1010
133
967
1.66
4.47
4.0
3.6
37.86
108.54
e6/l
0.95
89
667
47
250
2.04
4.42
5.3
4.6
0.56
0.88
%
—
9
73
294
2688
2.93
4.34
23.0
15.6
140.05
139.77
mmol/l
1.24
294
2637
17
56
3.15
4.31
1.2
1.0
1.20
0.91
u/ml
—
9
27
294
2691
2.91
4.27
23.1
15.7
3.96
3.95
mmol/l
0.32
294
2633
222
1853
1.70
4.24
4.7
3.8
—
20203.40
—
0
5
245
2104
1.79
4.19
5.1
4.4
14.51
14.58
pmol/l
0.17
233
1947
60
358
1.84
4.03
1.7
1.6
1261.66
1157.99
nmol/l
0.43
55
267
48
266
1.95
4.03
2.8
2.5
65.31
30.74
u/l
0.44
35
228
17
59
2.99
3.96
1.2
1.0
8.07
5.07
u/ml
—
10
37
72
462
1.73
3.78
3.3
2.6
535.12
546.70
mosm/kgh2o
0.16
66
410
8
12
6.81
3.69
1.8
6.8
18.97
16.28
%
—
8
12
120
883
1.59
3.67
2.5
3.3
2.36
2.35
mmol/l
0.22
109
811
34
172
2.10
3.66
3.5
3.3
5.40
5.11
kpa
1.17
34
167
44
247
1.91
3.56
5.5
4.5
7.36
7.39
ph
2.01
26
147
34
174
2.07
3.55
3.8
4.0
66.97
88.42
ng/l
1.44
29
157
112
818
1.58
3.51
5.0
6.6
—
—
—
0
0
275
2486
1.97
3.48
6.5
5.3
1.73
1.87
mu/l
1.18
266
2323
262
2335
1.80
3.45
23.1
17.3
13.67
13.46
%
1.15
262
2321
290
2682
2.32
3.30
18.5
13.9
19.98
21.87
mg/l
0.54
255
2151
17
66
2.67
3.27
1.3
1.1
0.47
2.17
u/ml
—
8
40
27
132
2.15
3.18
1.6
2.1
11.00
4.72
iu/ml
—
7
33
113
844
1.53
3.14
3.1
2.6
53.95
61.06
u/l
0.70
105
792
28
141
2.08
3.06
9.5
7.0
25.81
24.76
mmol/l
0.67
28
135
12
36
3.43
3.05
1.5
1.3
255.17
262.64
mu/l
0.06
12
28
25
121
2.16
3.02
3.6
3.4
—
—
—
0
0
29
150
2.03
2.96
6.3
4.4
24.77
24.27
mmol/l
0.31
29
150
41
241
1.81
2.88
1.4
1.6
—
—
—
0
0
52
328
1.70
2.88
4.3
2.5
7.14
7.56
umol/l
0.08
42
288
75
521
1.58
2.84
1.5
1.8
—
—
—
0
0
57
374
1.64
2.72
1.9
2.0
—
—
—
0
0
70
485
1.57
2.68
2.1
1.7
104918470.08
27990882.07
pmol/l
0.32
61
418
12
43
2.86
2.67
1.2
1.1
2.26
4.71
u/ml
—
6
22
13
49
2.73
2.66
1.2
1.0
2.42
1.20
u/ml
—
7
29
174
1455
1.45
2.62
3.7
3.5
0.00
0.01
estimate
0.50
34
283
16
68
2.43
2.60
2.3
4.1
57.26
64.17
%
0.45
16
68
34
196
1.83
2.56
2.1
3.1
73.21
74.13
e9/l
0.04
22
135
172
1447
1.43
2.44
3.7
3.5
0.00
5.38
estimate
0.50
37
302
13
52
2.57
2.39
2.5
2.4
90.82
89.98
%
0.21
13
52
170
1436
1.41
2.30
3.5
3.4
0.00
0.00
estimate
-0.00
38
305
10
34
3.00
2.30
3.5
2.9
—
—
—
0
0
8
23
3.54
2.28
1.3
1.3
97.62
102.65
pmol/l
—
8
23
6
13
4.68
2.28
1.0
1.0
—
—
—
0
0
82
608
1.47
2.27
1.5
1.9
1.21
1.09
mg/l
0.14
62
479
68
486
1.51
2.25
2.3
2.5
2.49
2.44
mmol/l
1.83
58
433
13
54
2.47
2.23
1.5
3.0
5.00
7.77
pmol/l
0.99
13
54
58
403
1.54
2.18
1.7
2.5
146.73
108.09
ug/g
0.55
46
322
11
42
2.68
2.16
1.0
1.6
—
—
—
0
0
9
30
3.06
2.16
2.1
1.3
—
—
—
0
0
16
75
2.20
2.12
12.9
5.4
1.11
1.23
mmol/l
0.39
16
67
18
89
2.09
2.10
2.7
2.3
24.36
24.63
mmol/l
0.09
18
89
49
331
1.57
2.08
1.2
1.2
—
—
—
0
0
13
56
2.38
2.07
1.2
1.1
—
—
—
0
0
12
50
2.46
2.05
1.2
1.0
—
—
—
0
0
14
63
2.28
2.04
1.2
3.1
1.40
3.04
ratio
—
6
38
22
119
1.91
2.03
2.0
2.2
—
—
—
0
0
8
26
3.13
2.02
1.0
1.5
—
—
nmol/l
—
0
0
15
72
2.14
1.89
3.1
3.1
8.68
8.35
kpa
0.26
15
72
84
646
1.41
1.89
1.6
1.4
1.89
2.37
g/l
3.08
53
411
18
93
1.99
1.89
3.8
3.7
24.41
24.72
mmol/l
0.18
18
87
92
721
1.39
1.86
1.4
1.3
2.84
1.78
u/ml
0.18
22
213
26
154
1.75
1.83
2.6
3.8
127.88
129.95
g/l
0.16
26
149
27
162
1.73
1.82
1.3
1.2
—
—
—
0
0
53
376
1.49
1.82
1.6
2.2
29.78
29.24
s
0.33
48
367
7
24
2.96
1.73
1.0
1.1
—
—
—
0
0
100
804
1.36
1.71
2.8
2.7
—
0.15
—
0
13
296
2840
2.00
1.70
24.1
17.5
68.87
74.23
umol/l
2.65
296
2808
117
967
1.34
1.67
4.5
3.4
56.89
34.11
ng/l
0.51
88
614
6
19
3.20
1.67
1.0
1.1
—
—
—
0
0
80
625
1.38
1.63
2.0
2.1
—
—
—
0
0
10
42
2.43
1.63
1.8
3.7
3.59
4.33
e9/l
—
10
42
43
299
1.51
1.63
1.7
1.4
—
—
—
0
0
136
1153
1.32
1.61
3.1
3.2
6.30
6.20
ph
0.51
74
669
51
369
1.46
1.59
3.1
3.0
3.84
6.34
e9/l
0.99
43
333
290
2772
1.75
1.58
16.7
12.2
—
—
—
0
0
72
556
1.38
1.57
2.9
2.4
6.57
5.70
e6/l
0.17
66
508
267
2507
1.48
1.56
6.8
5.8
38.29
38.66
mmol/mol
0.25
260
2378
37
252
1.53
1.54
1.2
1.2
—
—
—
0
0
51
374
1.44
1.49
1.5
1.3
—
—
—
0
0
270
2548
1.47
1.46
5.3
4.7
5.91
5.83
mmol/l
0.40
257
2379
217
1986
1.31
1.37
4.5
3.3
78.77
46.05
u/l
2.78
210
1900
5
17
2.97
1.36
2.4
5.1
11.12
8.18
mmol/l
—
5
17
5
17
2.97
1.36
1.0
1.0
—
—
—
0
0
71
563
1.34
1.31
1.4
1.3
18.10
28.38
iu/ml
1.10
23
171
5
18
2.81
1.29
1.0
1.3
—
—
—
0
0
11
55
2.04
1.29
1.9
3.5
54.70
56.72
%
0.32
11
55
8
35
2.32
1.28
1.5
1.5
17.66
37.47
ng/l
—
8
35
8
36
2.25
1.25
1.0
1.9
—
—
—
0
0
8
36
2.25
1.25
1.0
1.9
—
—
—
0
0
8
36
2.25
1.25
1.0
1.9
—
—
—
0
0
8
36
2.25
1.25
1.0
1.9
—
—
—
0
0
12
63
1.94
1.24
1.3
1.2
—
—
—
0
0
45
335
1.40
1.23
1.2
1.4
—
—
—
0
0
84
689
1.30
1.22
5.0
5.0
—
—
—
0
0
84
689
1.30
1.22
2.8
2.7
315.55
335.60
umol/l
1.16
74
618
8
37
2.19
1.22
1.6
1.4
58.88
58.31
mmol/l
—
8
32
15
87
1.76
1.17
1.1
1.2
—
—
—
0
0
5
20
2.52
1.15
1.0
1.1
—
—
—
0
0
106
904
1.26
1.13
3.2
3.2
7.18
8.15
mmol/l
1.26
86
772
98
833
1.26
1.07
2.9
2.8
0.00
0.01
estimate
0.80
34
249
9
48
1.90
1.01
1.1
1.2
—
—
—
0
0
13
76
1.74
1.00
1.7
2.6
—
—
—
0
0
126
1111
1.23
0.98
3.5
3.2
0.00
0.02
estimate
0.96
31
262
94
805
1.24
0.95
3.4
3.4
67.26
56.22
mg/l
0.16
58
509
29
392
0.71
0.95
1.3
1.5
—
—
—
0
0
64
524
1.28
0.95
1.4
1.3
13.17
10.29
u/ml
0.12
28
217
42
324
1.34
0.95
1.5
1.4
—
—
—
0
0
95
816
1.24
0.94
4.4
4.0
16.51
9.41
mg/mmol
0.38
57
498
18
118
1.56
0.93
1.1
1.2
—
—
—
0
0
33
246
1.38
0.92
2.1
2.1
0.00
0.00
estimate
-0.00
12
61
6
29
2.09
0.90
1.8
4.2
10.35
11.36
%
—
6
29
6
29
2.09
0.90
2.5
2.1
43.03
40.03
%
—
6
29
20
136
1.50
0.89
1.5
2.3
0.00
0.00
estimate
-0.00
11
50
99
859
1.22
0.89
2.4
2.3
—
—
—
0
0
91
784
1.23
0.87
3.5
3.6
0.00
0.01
estimate
0.74
36
288
13
80
1.65
0.86
1.2
1.3
284.59
306.07
ug/g
—
8
48
18
121
1.52
0.85
1.2
1.5
457.17
251.93
miu/ml
—
6
65
73
854
0.81
0.83
1.3
1.5
—
—
—
0
0
19
131
1.48
0.80
1.9
3.2
0.63
0.60
%
0.19
19
131
7
122
0.56
0.79
1.3
1.1
—
0.73
—
0
15
18
123
1.49
0.79
1.6
1.5
266.61
313.90
mu/l
0.57
18
113
10
162
0.60
0.79
1.3
1.7
—
—
—
0
0
75
642
1.22
0.76
3.8
3.5
1.02
1.02
kg/l
0.23
51
422
138
1253
1.18
0.74
2.6
2.7
—
—
estimate
—
0
0
119
1070
1.18
0.71
2.1
2.0
—
—
—
0
0
5
27
1.87
0.68
2.4
1.3
29.00
32.74
pg
—
5
27
10
62
1.63
0.66
1.4
1.3
—
—
—
0
0
107
1178
0.86
0.60
3.6
3.0
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
27
212
1.30
0.58
2.6
2.2
5.72
6.08
ph
1.47
16
134
28
224
1.27
0.53
1.3
1.4
—
—
—
0
0
80
716
1.16
0.50
4.7
4.5
1.47
1.73
ug/l
0.56
75
649
9
127
0.70
0.44
1.2
1.1
1.64
1.56
g/l
—
9
127
7
51
1.38
0.44
2.1
2.0
3.69
5.16
mmol/24h
—
7
43
228
2357
0.88
0.44
25.0
17.7
331.45
333.22
g/l
1.87
228
2346
28
337
0.81
0.44
2.0
1.8
—
—
—
0
0
5
32
1.57
0.42
1.6
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
12
88
1.38
0.40
2.6
4.6
663.29
252.90
mg/l
—
7
40
5
34
1.48
0.40
1.0
1.2
—
—
—
0
0
128
1200
1.11
0.39
2.1
2.0
1.54
1.42
mmol/l
0.96
109
1028
5
36
1.40
0.38
1.0
1.2
—
—
—
0
0
23
191
1.22
0.34
1.1
1.4
—
34.44
—
0
18
6
86
0.69
0.33
24.7
9.0
—
—
—
0
0
261
2662
0.87
0.33
5.7
4.8
1.54
1.47
mmol/l
1.31
248
2499
7
54
1.30
0.30
3.3
3.6
—
—
—
0
0
10
130
0.76
0.30
1.9
1.1
0.79
0.92
g/l
—
10
130
14
112
1.26
0.29
4.0
3.0
1.02
1.02
ratio
0.21
14
107
249
2539
0.90
0.27
4.9
4.1
1.44
1.29
mmol/l
2.37
234
2373
11
86
1.29
0.26
2.1
1.9
—
—
—
0
0
21
180
1.18
0.24
1.1
1.1
—
—
—
0
0
6
84
0.71
0.24
1.5
1.8
—
—
—
0
0
5
40
1.25
0.22
1.2
1.3
—
—
—
0
0
5
41
1.22
0.22
1.0
1.2
—
—
—
0
0
23
201
1.16
0.22
1.3
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
4.1
—
9.32
—
0
14
0
14
0.00
0.20
0.0
2.6
—
53.20
—
0
5
264
2670
0.92
0.16
5.8
4.9
4.83
4.72
mmol/l
0.99
252
2525
6
76
0.79
0.16
1.3
1.3
—
—
—
0
0
10
83
1.21
0.15
1.7
1.2
—
—
—
0
0
17
150
1.14
0.15
1.9
1.6
0.41
0.35
mg/l
0.12
12
63
46
432
1.08
0.14
2.8
2.8
0.52
0.74
ug/l
2.16
28
258
25
233
1.08
0.09
1.4
1.3
90.94
144.23
u/ml
—
8
102
6
56
1.07
0.08
1.3
1.9
—
—
—
0
0
5
65
0.77
0.08
1.2
1.1
—
—
—
0
0
5
65
0.77
0.08
1.2
1.1
—
—
—
0
0
11
123
0.89
0.08
1.3
1.3
—
—
—
0
0
6
71
0.84
0.07
1.7
1.8
—
—
—
0
0
20
214
0.93
0.07
3.1
3.1
—
—
—
0
0
26
247
1.06
0.06
3.2
4.7
7.03
54.21
ug/l
0.81
20
200
15
141
1.07
0.03
1.0
1.1
—
—
—
0
0
269
2700
0.97
0.03
6.2
5.5
2.79
2.79
mmol/l
0.00
256
2543
16
158
1.01
0.00
1.3
1.7
—
—
—
0
0
16
157
1.02
0.00
1.3
1.7
—
—
—
0
0
16
157
1.02
0.00
1.3
1.7
—
—
—
0
0
10
105
0.95
0.00
2.7
1.6
—
—
—
0
0
16
155
1.03
0.00
1.3
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
57.60
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
6.12
—
0
5
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
73.68
—
0
5
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.0
—
48.08
—
0
6
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
15
150
1.00
-0.00
1.3
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
6.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint G6_MYOTDIS and mortality.

Females

Parameter HR [95% CI] p-value
G6_MYOTDIS 3.443 [2.74, 4.32] < 0.001
Birth year 0.991 [0.98, 1.0] 0.048

During the follow-up period (1.1.1998 — 31.12.2019), 168 out of 957 females with G6_MYOTDIS died.

Males

Parameter HR [95% CI] p-value
G6_MYOTDIS 3.471 [2.87, 4.19] < 0.001
Birth year 0.99 [0.98, 1.0] 0.069

During the follow-up period (1.1.1998 — 31.12.2019), 219 out of 898 males with G6_MYOTDIS died.

Mortality risk

Mortality risk for people of age

years, who have G6_MYOTDIS.

N-year risk Females Males
1 0.244% 0.863%
5 1.687% 4.271%
10 4.616% 10.427%
15 8.129% 20.038%
20 13.812% 32.6%

Relationships between endpoints

↥

Index endpoint: G6_MYOTDIS – Myotonic disorders

GWS hits: 26

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data